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THE EFFECT OF CHLORAMPHENICOL ON BB88
MURINE ERYTHROLEUKEMIA CELLS

Peter K. W. Harris, Ph.D.
Western Michigan University, 2007

DNA microarrays can be used to measure genome-wide transcript levels. These
measurements may be useful in understanding cellular changes induced by a chemical
agent. In this study, Affymetrix microarray technology has been used to study the
effects of chloramphenicol, an antibiotic that inhibits bacterial and mitochondrial
protein synthesis, on the transcription profile in mammalian cells. Transcript levels in
BB 88 murine erythroleukemia cells treated with 50 micromolar (pM) chloramphenicol,
a concentration shown to inhibit BB 88 proliferation, are measured. Using total RNA
from treated cells, biotin-labeled cRNA was prepared and hybridized to Affymetrix
U74Av2 microarrays. From these hybridizations, expression levels were measured for
approximately 12,000 transcripts. Methods to identify genes whose transcript levels
increase or decrease during the treatments are described. In particular, chloramphenicol
increases transcript levels for a subunit of cytochrome c oxidase (COX), a complex
metalloprotein that plays a critical role in cellular respiration. Specifically, transcripts
for cytochrome c oxidase Vla-H (COX Vla-H), a nuclear-encoded subunit of complex
IV in the mitochondrial respiratory chain, increase greater than 20-fold after 24 hours of
chloramphenicol treatment. While transcripts for COX Vla-H are increased in
chloramphenicol-treated cultured erythroleukemia cells, transcripts for other nuclear-
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encoded COX subunits appear unaffected. To follow-up on these findings, a reverse
transcription-polymerase chain reaction (Taqman® PCR) method has been used to
confirm that chloramphenicol causes specific increases in COX Vla-H expression in
these cells not shown previously to contain COX Vla-H. Further, these results have
been extended by showing that increases in the COX Vla-H transcript by
chloramphenicol treatment are concentration- and time-dependent. Finally, in cells
treated with other compounds that inhibit either mitochondrial protein synthesis or
respiration, COX VTa-H transcripts are increased. While chloramphenicol’s mechanism
of mammalian cell toxicity remains uncertain, these findings support evidence that
shows chloramphenicol has an affect on mitochondrial proteins and suggests the COX
Vla-H transcript may be an anti-proliferation marker (biomarker) in these cells.
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INTRODUCTION
Antibiotics: Mechanism of Action and Toxicity
Antibiotics are compounds that either stop microorganisms from growing or kill
bacteria or fungi outright. In the 1940s, Selman Waksman, a 1952 Nobel laureate, used
the term “antibiotic” to describe any antimicrobial compound that was derived from a
living organism having therapeutic potential versus infectious diseases (Waksman &
Geiger, 1944). Today, the term antibiotic is more inclusive and applies not only to
natural, synthetic, or semi-synthetic agents that are used to treat infectious microbes, but
also to natural products that can inhibit growth of human cancer cells. An antibiotic that
inhibits the growth of bacteria is called bacteriostatic; chloramphenicol exemplifies this
kind of antibacterial compound. Antibiotics that lower bacterial cell number by causing
death are called bactericidal and penicillin exemplifies this kind of antibiotic. As
mentioned above, while there are some man-made antibiotics, such as the sulfonamides,
antibiotics are produced primarily by microorganisms. This production is probably an
evolutionary adaptation so that the antibiotic producer has an advantage over its
antibiotic-sensitive neighbors. Both bacteria and fungi synthesize antibiotics. However,
since antibiotics often target cellular components or metabolic pathways unique to
another group of organisms, it is rare for a specific antibiotic to be therapeutically useful
as both an antibacterial and an antifungal. Antibacterial antibiotics will be discussed
briefly, in part due to the current diversity of these therapeutic agents, and in particular,

1
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due to the research described herein that focuses on toxicity of chloramphenicol, a
broad-spectrum antibacterial antibiotic. The following paragraphs highlight mechanistic
aspects and toxicity issues for some important antibacterial drugs, with only a brief
mention of antibiotic selectivity and resistance.
There are several systems of classifying antibiotics. One classification system is
based upon on the producing organisms. Of the approximately 12,000 known
antibiotics, about 160 have been used in human therapy. Streptomyces, a genus of grampositive (see below), filamentous bacteria found predominantly in soil and in decaying
vegetation, is estimated to be responsible for 55% of the commercially available
antibiotics (Champness, 2000). Another classification method is by spectrum of activity
or the bacterial diseases they are used to treat (Levy, 1998). Some antibiotics are used in
specific situations and against particular pathogens. For instance, bacitracin is used
topically versus skin infections, while tetracyclines can be used internally versus
infections of the digestive and urinary tracks. Historically, antibiotics were discovered
based upon their effect on bacterial growth. It was not until later that an antibiotic’s
mode of action, selectivity, and toxicity, were made known. Through this information,
perhaps the most common system of antibiotic classification is grouping compounds
based upon their mode of action. There are four prime antibacterial metabolic targets:
1) cell wall synthesis, 2) protein synthesis, 3) DNA and RNA synthesis, and 4) folic acid
metabolism (nucleotide precursor biosynthesis). Two of these targets, cell wall
biosynthesis and folic acid metabolism do not have human counterparts. The other two
targets, protein synthesis and DNA and RNA synthesis, are found in humans, but there
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are enough structural differences that selective inhibition of disease causing bacteria has
been achieved.
Antibiotics That Inhibit Cell Wall Synthesis
In the 1880s, Hans Gram (1884), a Danish bacteriologist, developed a stain to
distinguish strains of bacteria. At the time Gram did not know how the stain worked, but
later scientists learned that the Gram reaction is based on the structure of the bacterial
cell wall (Popescu & Doyle, 1996). In gram-positive bacteria, an iodine-crystal violet
complex is trapped in the outermost peptidoglycan (PG) layer of the cell wall and these
cells appear purple under the microscope. This iodine-crystal violet complex also binds
to the peptidoglycan layer that lies beneath the outer membrane in gram-negative
bacteria. However, it is washed away along with the outer membrane upon exposure to
ethanol. Subsequent counterstaining with safranin or basic fuchsin causes the decolorized
gram-negative bacteria to appear pink. While other components of bacterial cell walls
have been targets, it is this PG that has been successfully targeted by many antibiotics.
These antibiotics have been involved in inhibiting enzymes or sequestering substrates
involved in PG biosynthesis.
PG biosynthesis occurs in three phases (Figure 1). During the cytoplasmic phase,
six enzymes, Mur A-F, are responsible for converting UDP-N-acetylglucosamine to
UDP-muramyl-pentapeptide (El Zoeiby, Sanschagrin, & Levesque, 2003). While
research into inhibitors for the cytoplasmic phase of PG synthesis is flourishing,
fosfomycin, an antibiotic used to treat infections of the urinary tract by inhibiting MurA,
is about the only antibiotic that has been used in humans (F. Kahan, J. Kahan, Cassidy, &
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Figure 1. Antibiotics That Inhibit Cell Wall Biosynthesis, (courtesy of Walsh, 2003)

Kropp, 1974; Skarzynski et al., 1996). During the membrane-associated phase, MraY
transfers the muramyl-pentapetide to an unusual membrane lipid, bactoprenol, creating
Lipid I (Bouhss, Crouvoisier, Blanot, & M^ngin-Lecreuix, 2004; Ikeda, Wachi, Jung,
Ishino, & Matsuhashi, 2001; Van Nieuwenhze, Mauldin, Zia-Ebrahimi, Aikens, &
Blaszczak, 2001). Tunicamycin, a natural antibiotic commonly used in eukaryotic
glycoprotein research, inhibits this reaction, whereas the mureidomycins selectively
inhibit prokaryotic MraY (Lee & Hecker, 1999). Next, the essential MurG converts
Lipid I to Lipid II by adding a UDP-N-acetyl glucosamine to the UDP-muramylpentapeptide (Ha, D. Walker, Shi, & S. Walker, 2000; Ha, Gross, & S. Walker, 2001).
While not exactly understood, Lipid II translocates the disaccharyl-pentapetide from the
internal membrane to the external membrane face. Bacitracin, a decapeptide, inhibits
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transglycosylation by interactions with Lipid II (Brotz, Bierbaum, Leopold, Reynolds, &
Sahl, 1998). Originally, the lipoglycodepsipeptide, ramoplanin, was thought to inhibit
MurG, but recent research implies that this antibiotic inhibits the transglycosylation step
of PG biosynthesis by binding to Lipid II (Fang et al., 2006).
The final phase of PG biosynthesis involves several separate reactions occurring
in the external space outside o f the bacterial internal membrane. First, enzymes called
autolysins break both glycosidic bonds at the point of growth along the existing
peptidoglycan and the peptide cross-bridges that link the rows of sugars together.
Transglycosylases then insert the PG monomers from Lipid II into the breaks in the
mature PG. Transpeptidases reform the peptide cross-bridges between the rows and
layers of PG to make the cell wall strong osmotically. The glycopeptides, vancomycin
and teicoplanin, complex with the pentapeptide portion of PG and Lipid II. This
interaction effectively sequesters the PG from not only transpeptidases, but also
transglycosidases. Since the outer membrane limits their access to PG in the periplasm,
vancomycin and teicoplanin have little effect on most gram-negative bacteria. However,
there has been some work on semi-synthetic glycopeptides that can cross the outer
membrane of vancomycin insensitive bacteria (Ciabatti & Malabarba, 1997).
Moenomycin is one of the few antibiotics that interferes with transglycosylation. NMR
structural studies have revealed that it binds to the target transglycosylase and blocks
disaccharyl-pentapeptide addition to a growing PG layer (Kurz, Guba, & Vertesy, 1998).
P-lactams are a class o f antibiotics that interfere with PG transpeptidation reaction.
Penicillins and cephalosporins are perhaps the most celebrated natural P-lactams. The
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story of Alexander Fleming’s accidental discovery of penicillin in 1928 is well known
(Fleming, 1932, 1945, 1980); but what is not so well remembered is that it took more
than ten years before scientists, Chain and Florey, had enough of the antibiotic purified
for large-scale clinical use (Chain et al., 1940). While these three researchers shared
equally a Nobel Prize in 1945, arguably it is Fleming who is best remembered. Some
have suggested that the public adulation for Fleming was not only for his pioneering
scientific work, but also because of his friendly and outgoing personality. Further, after
one of his patients died on account of there not being enough antibiotic to complete the
treatment, Howard Florey shied away from publicity (Bennett & Chung, 2001).
Nevertheless, another quarter century passed before penicillin’s mechanism of action was
better understood. In Jack Strominger’s lab at Harvard, it was proposed that the Plactam portion of penicillin mimicked the acyl-D-alanyl-D-alanine structure on the PG
pentapeptide chain (Tipper & Strominger, 1965). Experiments showed that when
transpeptidases bind to P-lactams, the enzyme-antibiotic intermediates are extremely
stable. This binding effectively inhibits the transpeptidation reaction, resulting in a
weakly cross-linked cell wall and osmotic lysis of the bacterium (Strominger, Blumberg,
Suginaka, Umbreit, & Wickus, 1971; Yocum, Rasmussen, & Strominger, 1980).
Although the penicillins and cephalosporins are some of the most successful and widely
used antibiotics, newer semi-synthetic P-lactams have been developed over the years
(Scholar & Pratt, 2000). While the mechanism of action remains the same, these newer
P-lactams are overcoming some of the issues experienced with the older antibiotics, such
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as degradation by stomach acids, resistance to bacteria that produce penicillinases, and
increased range of activity versus some Gram-negative bacteria.
Antibiotics That Inhibit Protein Synthesis

The second antibacterial metabolic target is protein synthesis (Figure 2). Protein
synthesis is not unique to prokaryotes, as the process is an essential function for all cells.
However, there exist enough differences between the eukaryotic and prokaryotic protein
synthetic machinery to make this metabolic process an effective antibacterial target. Most
protein synthesis antibiotics target the ribosome. The 70S bacterial ribosome consists of
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Figure 2. Antibiotics That Inhibit Bacterial Protein Synthesis, (courtesy of Walsh, 2003)

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

two nucleoprotein subunits. While the smaller 3OS subunit contains a 16S ribosomal
RNA (rRNA) and about 20 proteins, the larger 50S subunit is made up of a 23 S rRNA, a
5S rRNA and about 30 proteins. The recent articles describing the crystal structures for
the 30S, 50S, and the intact 70S ribosomal subunits have deepened our understanding of
protein synthesis and the mechanisms involved in mRNA translation (Ban, Nissen,
Hansen, Moore, & Steitz, 2000; Nissen, Hansen, Ban, Moore, & Steitz, 2000;
Ramakrishnan, 2002; Wimberly et al., 2000). Each 30S and 50S subunit has three
binding sites for transfer RNA (tRNA). The A-site accepts incoming aminoacylatedtRNA. The P-site holds the tRNA with the nascent polypeptide chain, while the E-site
holds the de-acylated tRNA before it leaves the ribosome. The 30S ribosome binds
mRNA and the anticodon subunits of tRNA. This subunit contributes to translation
fidelity by monitoring base pairing between codon and anticodon. The 50S subunit
catalyzes peptide bond formation between incoming amino acids on A-site tRNA and the
nascent polypeptide chain attached at the neighboring P-site tRNA. Besides mRNA,
tRNA, and the ribosome, bacterial protein synthesis requires additional proteins. Many of
these proteins are GTP binding proteins that become activated upon ribosome binding
and then aid in protein synthesis initiation, elongation, and termination (Nissen 2000).
Tetracycline and the aminoglycoside antibiotics affect protein synthesis by
binding to the 16S rRNA of the 3OS ribosomal subunit. Structural studies showed that
tetracycline, a bacteriostatic antibiotic that has been around for more than 50 years, binds
to the A-site on 16S ribosome (Carter et al., 2000). While tetracycline’s binding does not
appear to block the initial delivery of aminoacyl-tRNA to the ribosome and the
accompanying hydrolysis of GTP by initiation factors, it does cause premature
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aminoacyl-tRNA release without peptide bond formation (Brodersen et al., 2000, 2001).
The aminoglycoside streptomycin was discovered in 1943 in the laboratory of Selman
Waksman, who later won a Nobel Prize for its discovery. As an aside, this Nobel Prize
has been accompanied by some controversy (Mistiaen, 2002). With some strong
evidence to support his claims, Albert Schatz, a young scientist working for Waksman at
the time, claimed not only to have discovered streptomycin, but first demonstrated that it
was active against the tuberculosis bacterium, Mycobacterium tuberculosis (Schatz &
Waksman, 1944; Schatz, Bugie, & Waksman, 1944). While some issues were resolved
legally, this situation created some very hard feelings and tarnished reputations. As are
most aminoglycosides, streptomycin is a hydrophobic sugar with multiple amino groups
attached. The aminoglycosides are bactericidal versus most gram-negative bacteria and
resistance mapping studies have shown that most of the mutations were found to map to
a region close to the tetracycline binding site (Carter, 2000; Springer, 2001). However,
since they are ineffective versus gram-positive bacteria, they have been used
synergistically with some P-lactam antibiotics (Scholar & Pratt, 2000).
The macrolides are a small group of natural bacteriostatic antibiotics that inhibit
protein synthesis by acting at the 50S ribosome. Structural, mutational, and footprinting
studies have revealed that macrolide antibiotics like erythromycin interact with
nucleotide residues between 2040-2609 on the 23 S rRNA, a region at the entrance of the
polypeptide export tunnel (Schlunzen et al., 2001; Vester & Douthwaite, 2001; GarzaRamos, Xiong, Zhong, & Mankind, 2001). Binding of these antibiotics and certain semi
synthetic macrolides, such as azithromycin, disrupts the elongation step in protein
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10
synthesis (Ramakrishnan, 2002). The antibiotic clindamycin, despite being structurally
different, is a competitive inhibitor of erythromycin and inhibits protein synthesis by
binding to the 23 S rRNA at or near physically overlapping sites (Douthwaite, 1992a).
Similarly, chloramphenicol, which will be discussed later, inhibits bacterial protein
synthesis by interactions with 23 S rRNA (Douthwaite, 1992b; Long & Porse, 2003).
The oxazolidinones are a class of compounds that inhibit bacterial protein
synthesis. Linezolid, an oxazolidinone that was approved by the FDA in 2000, is the first
structurally novel antibiotic introduced in the last three decades. Early mutational
studies of linezolid-resistant bacteria strongly suggested that this synthetic antibiotic
interferes with protein synthesis by binding to a site that is near to the peptidyl
transferase center on the 50S ribosome (Kloss, Xiong, Shinabarger, & Mankin, 1999;
Zhou, Swaney, Shinabarger, & Stockman, 2002). Using a photoactive probe, Colca et al.
(2003) localized the site of oxazolidinone action in Staphyloccocus aureus. In addition to
cross-linking to the conserved adenine nucleotide at position 2602 on the 23 S rRNA, the
photoactive oxazolidinone cross-linked ribosomal protein L27, whose amino terminus
may reach the peptidyltransferase center, and LepA, a protein homologous to translation
factors.
Antibiotics That Inhibit DNA and/or RNA Synthesis

DNA and RNA synthesis are the third group of antibacterial metabolic targets.
DNA gyrases are essential bacterial enzymes that introduce negative DNA supercoils
into a double-stranded circular DNA (Figure 3). These negative supercoils release
superhelical tension ahead of DNA polymerase so that replication can continue
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(Cozzarelli, 1980). The fluoroquinolones are a synthetic class of bactericidal antibiotics
that block DNA synthesis by inhibiting DNA gyrase. DNA gyrase exists as a heterodimer
and biochemical and genetic studies have identified the A subunit (GyrA) as a target of
ciprofloxacin and other quinolones (Hooper, Wolfson, Ng, & Swartz, 1987). Quinolone
resistance mutations frequently occur at residues Ser83 and Asp87 of the gyrase A subunit,
suggesting that these residues are involved in drug binding (Barnard & Maxwell, 2001).
However, recently the B subunit (GyrB) has been implicated in quinolone binding, as
antibiotic resistance mutations are known to exist in GyrB. In vitro, two such mutant
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proteins, GyrB (Asp426—*Asn) and GyrB(Lys447-* Glu), have been shown to behave
similarly to GyrA quinolone-resistant proteins by decreasing the amount of radio-labeled
ciprofloxacin bound to a gyrase-DNA complex (Heddle & Maxwell, 2002). Bacterial
gyrases and the eukaryotic enzyme topoisomerase II are similar. However, enough
differences exist between the two enzymes such that the quinolones selectively inhibit
gyrases while topoisomerase II remains resistant. In terms of RNA synthesis, another
antibacterial metabolic target that has a eukaryotic counterpart, rifampicin (rifampin) is
the only antibiotic in clinical use. Rifampicin is a semisynthetic version of Rifamycin B, a
natual product isolated from Nocardia mediterranei fermentations (Sensi, 1983). This
antibiotic, which has been a key component of tuberculosis therapy, binds to the
P subunit o f RNA polymerase. X-ray structures of rifampicin bound to the core RNA
polymerase of Thermus aquations revealed that this antibiotic blocks RNA elongation by
binding in the DNA/RNA tunnel (Campbell et al., 2001).
Antibiotics That Inhibit Folic Acid Metabolism
The fourth primary antibacterial metabolic target is folic acid metabolism (Figure
4). Folic acid functions as a coenzyme in the pathway leading to purine nucleotide
synthesis. Animals cannot synthesize folic acid and depend on exogenous sources.
Therefore, animal cells are unaffected by inhibitors of the bacterial folic acid pathway.
Sulfamethoxazole and trimethoprim are two drugs which block steps in bacterial folic
acid metabolism. These two drugs are being used in combination to treat patients with
unrinary tract infections and also acquired immunodeficiency syndrome (AIDS) patients
with Pneumocystis carinii infections (Scholar & Pratt, 2000). Sulfamethoxazole is a
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Figure 4, Antibiotics That Inhibit Folic Acid Metabolism, (courtesy of Walsh, 2003)

current generation sulfonamide. In his book, The Demon Under the Microscope, Thomas
Hager (2006) argued that the key event in the history of antibacterials was not the
emergence of penicillin in the 1940s, but Gerhard Domagk’s discovery and the
development o f sulfonamides almost a decade earlier. In 1932, while working as a
bacteriologist in a large German company, Domagk took chemicals originally introduced
into the dye industry and tested them for their antibacterial activity. He found that a
synthetic sulfonamide preparation, subsequently named Prontosil, cured mice infected
with ten times the leathal dose of Streptococcus (Domagk 1935, 1937). An interesting
point Hager makes is that, while Domagk was awarded a Nobel Prize in 1939 for this
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work, two ironies existed to explain why his momentous work did not receive greater
acclaim. First, Domagk worked in Nazi Germany and was not allowed to travel to
receive his award. Second, Domagk’s employer, IGFarben, became the major producer
of poison gas that was used to kill Jews in the concentration camps. Hager argues that
here is how politics and social situations can impact the importance or significance of a
scientific discovery. Much later it was shown that the structure of sulfonamides
resembles that of para-aminobenzoic acid (PAB A), a precursor in folic acid synthesis,
and sulfonamides compete for binding with PABA for the enzyme dihydropteroate
synthase. In 1997, crystal structures of sulfonamide with the bacterial enzyme validated
this mechanism of inhibition (Achari et al., 1997). In the case of the antibiotic
trimethoprim, this compound inhibits bacterial dihydrofolic acid reductase, an enzyme
that converts dihydrofolic acid to tetrahydrofolic acid, a step later in the bacterial folic
acid metabolic pathway. While this enzyme exists in humans, the IC50s for the bacterial
and human enzymes are 10 nM and 300,000 nM, respectively (Scholar & Pratt, 2000).
Thus, in combination with the sulfonamides, trimethoprim blocks the synthesis of
nucleotides that will be used in bacterial DNA and RNA synthesis.
Antibiotic Toxicity
Antibiotics have been tremendous assets in the treatment of infectious diseases.
However, even though many antibiotics follow the principle of selective toxicity,
antibiotic therapy is not without some risk. In fact, even though the antimicrobial target
may not be present in humans, most antibiotics have the potential to be toxic. Antibiotic
adverse reactions can be classified as either dose-dependent or non dose-dependent. In
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dose-dependent adverse reactions, the incidence and intensity of adverse effects increase
proportionately to antibiotic concentration. Patient monitoring, considerations of patient
pharmacokinetic differences, and dosage individualization can decrease these adverse
reactions. Non dose-dependent adverse reactions are less common but are more severe.
They are considered idiosyncratic, suggesting that the exact mechanism is unknown.
These adverse reactions don’t depend upon antibiotic pharmacodynamics, but appear
related to a patient’s immune system or the genetics of drug metabolism. These kinds of
adverse reactions appear unexpectedly and often cause death (Gruchalla, 2001 ;
Wawruch, Bozekova, Kremery, & Kriska, 2002).
Toxicity of Cell Wall Inhibitors
Despite penicillin and its many semi-synthetic derivatives being relatively
nontoxic even at high doses, their use leads frequently to allergic reactions. These
allergic reactions to p-lactams are mediated by an immune mechanism. Most antibiotics
are chemically inert in their native state and need to be metabolized in order to covalently
bond with other macromolecules. In the case of penicillin, and other P-lactams,
degradation occurs spontaneously in the body and the intermediates bind to proteins.
These protein bound intermediates are immunologically reactive (Solensky, 2003, 2006).
Interestingly, while penicillin sensitivity has been estimated to be 10% of the general
population, this estimate may be inaccurate. In a study where patients with a penicillin
allergy were re-evaluated by a skin test, more than 90% were found not to be allergic
and were able to tolerate the antibiotic (Gadde, Spence, Wheeler, & Adkinson, 1993).
The discrepancy here may be explained by several factors. The initial allergic reaction
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may have been unrelated to the antibiotic and caused by the illness or the loss of
penicillin-specific IgE antibodies over time (Solensky, 2006). Vancomycin has been quite
effective in the treatment of methicillin-resistant Staphylococcus aureus infections.
Except for some allergic reactions, the major side effects of this antibiotic are
nephrotoxicity and ototoxicity. While the mechanism of kidney toxicity is not completely
understood, biochemical and histological analyses of rats treated seven days with
vancomycin (200 mg/kg) revealed increased blood levels of urea/creatinine and
destruction to glomeruli and necrosis of proximal tubules, respectively (Nishino et al.,
2003). Thus, these researchers suggest oxidative stress might underlie the pathogenesis
of vancomycin-induced nephrotoxicity because targeting the antioxidant superoxide
dismutase to the kidneys reduces the damage caused by this antibiotic. In terms of
vancomycin and ototoxicity, some studies suggest that this adverse effect may be a result
o f vancomycin-induced augmentation of aminoglycoside ototoxicity, see below.
However, in animal models, vancomycin given alone at high doses causes no hearing
damage (Brummett, 1993).
Toxicity of Protein Synthesis Inhibitors

The adverse effects of the aminoglycosides are dose-dependent and can be
manifested by nephrotoxicity and ototoxicity. There seems to be two contributing factors
here. Aminoglycosides have a narrow therapeutic concentration range and patients
present with a wide variation in antibiotic tissue distribution and elimination
characteristics (Garraffo, 1998). Large amounts of intravenous administered
aminoglycoside accumulate in the kidney (about 10% of dose), whereas little distribution
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of aminoglycosides to other tissues is observed (Nagai & Takano, 2004). In patients with
normal serum creatinine levels, Zaske and coworkers (1982) observed half-lives of
gentamicin between 0.4 and 32.7 hours (Zaske, 1982). It is felt that patients with longer
gentamicin half-lives accumulate more of this antibiotic in the kidney and inner ear.
Recently, there have been some links made between adverse antibiotic effects and
mitochondrial protein synthesis (MPS). Since MPS machinery is similar to prokaryotic
machinery, antibiotics that bind to prokaryotic ribosomes may also target mitochondrial
ribosomes (Bottger, Springer, Prammananan, Kidan, & Sander, 2001). In a recent study
on the oxazolidonones, results indicate that this class of antibiotic inhibits mammalian
MPS in a variety of tissues (McKee, Ferguson, Bentley, & Marks, 2006). In addition to
the oxazolidinones, of eight clinically approved antibiotics studied, only chloramphenicol
and tetracycline were significant inhibitors of mammalian MPS. While chloramphenicol
toxicity is a prime focus this work and will be discussed in detail later, the oxazolidinones
and chloramphenicol have been linked to dose-dependent reversible suppression of bone
marrow synthesis. Some have argued that severe clinical consequences result from the
oxazolidinones inhibiting MPS (De Vriese et al., 2006). Interestingly, the macrolides,
lincosamides, and aminoglycosides are relatively poor inhibitors of MPS; and of these
three types of antibiotics, the macrolides and lincosamides are well tolerated and
associated with few adverse effects.
Toxicity of DNA and/or RNA Synthesis Inhibitors
The most common adverse reactions of quinolones are effects to the
gastrointestinal tract and the central nervous system. Although some gastroinstestinal
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problems could be related to antibiotic neurotoxicity, they arise probably from effects on
the normal flora. Digestive bacteria may be sensitive to fluoroquinolones and other
antibiotics, so that the symbiotic relationship that exists between the gastrointestinal
system and bacteria is disrupted (Stahlmann, 2002). While the pathogenesis of
neurotoxicity is still unknown, it may be related to inhibition of the y-aminobutyric acid
receptors or possibly to agonism of N-methyl-D-aspartate receptors (Ito, Miyasaka,
Fukuda, Akahane, & Kimura, 1996; Lode, 1999). Using electrophysiological
determinations on hippocampal slices, several fluoroquinolones increased the neuronal
population spike amplitude in a concentration-dependent manner (Schmuck, Schurmann,
& Schulter, 1998). An important point here is that antibiotic toxicity can be interpreted
differently. For example, there have been several fluoroquinolones removed from the
market due to severe toxicities. As an example, temafloxacin was withdrawn in 1992
after a uremic syndrome involving hemolysis, renal failure, and thrombocytopenia was
associated with its use (Norrby & Lietman, 1993). The syndrome was estimated to occur
in about one in 5000 patients treated with this antibiotic. This incidence was too low to
detect during the clinical trials. From this perspective, antibiotic drug discovery is very
difficult. Erythromycin and other newer fluoroquinolones have shown some cardiac
effects. In vitro and in vivo studies have shown that erythromycin exerts
electrophysiologic effects on the cardiac muscle. In a hospital study, doctors observed
prolongation in QT intervals in EKGs of 15 patients who were being treated with
intravenous erythromycin for simple pneumonia (Freeman & Platt, 1997). However,
recent dog studies showed that the quinolone, moxifloxacin, and the erythromycin
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analogue, azithromycin did not cause ventricular problems when compared with the
control compound, dofetilide (Thomsen et al., 2006). Thus, there are some unresolved
issues with the cardiac effects of these antibiotics. When used to treat tuberculosis,
rifampicin has been associated with some dose-dependent adverse reactions. Most
common were its gastrointestinal effects. However, this antibiotic has been shown to
inhibit bilirubin transport and this hepatic effect may warrant monitoring liver chemistry
(Yew & Leung, 2006).
Toxicity of Inhibitors of Folic Acid Metabolism
Antibiotics that target folic acid metabolism have some associated adverse
reactions. The sulfonamides have been shown to cause hypersensitivity, nephrotoxicity,
and hepatotoxicity. Hypersensitivity is the most common side effect of sulfonamide
treatment and a possible mechanism by which antibiotics can invoke an immune response
has been discussed already. Sulfonamides can cause renal insufficiency by precipitating in
the kidney, especially in patients who already have an underlying kidney deficiency.
Prevention and treatment includes drug dose monitoring, adequate hydration, and
drinking alkaline mineral waters (Perazella, 1999). Idiosyncratic sulfonamide-induced
hepatotoxicity may result from antibiotic metabolism. Sulfonamides are metabolized
primarily by acetylation. Certain patients acetylate sulfonamides more slowly resulting in
more of the antibiotic passing through the cytochrome P-450 pathway system. This
system produces reactive toxic metabolites that are normally detoxified by scavenger
compounds such as glutathione. In some patients known to have low levels of
glutathione, these sulfonamide metabolites accumulate and are hepatotoxic (Larrey &
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Pageaux, 1997). Also, patients who are slow acetylators have a higher incidence of
sulfonamide hypersensitivity reactions (Carr, Gross, Hoskins, Penny, & Cooper, 1994;
Rieder, Shear, Kanee, Tang, & Spielberg, 1991).
The essence of antimicrobial chemotherapy is selective toxicity. To be effective,
antimicrobial agents must possess a selective action on microorganisms without being
toxic to the host cells. Here some of the primary antibacterial mechanisms along with
their potential toxicities have been described. As has been discussed, even though some
antibacterial targets have no human counterpart, adverse reactions occur. Antibiotics can
be recognized as foreign, eliciting an immune response, while some antibiotics become
metabolized and it is these metabolites that are immunogenic or toxic. Accompanying the
molecular biology and genomic revolutions is a deeper understanding of the similarities
and differences between prokaryotic and eukaryotic cells (Fischer & Freiberg, 2007;
Schnappinger, 2007). With the genomes of several pathogenic bacteria being sequenced
completely, new essential and unique genes have been identified. Researchers are trying
to see if they can synthesize chemicals that will not only affect these novel targets, but
also not be toxic to the bacteria’s host (humans). Hopefully, this work will delineate
new antibiotic targets to counteract not only the growing problems of antibiotic
resistance, but also issues with antibiotic toxicity.

Studies of Gene Expression
Gene expression is a process by which the hereditary information encoded in a
gene’s DNA sequence is converted into the structures and metabolic functions of a cell.
This conversion is the result of transcription and translation, whereby DNA gets
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transcribed into messenger RNA (mRNA) and the mRNA gets translated into protein.
These two processes contribute to a dogma that forms the fundamental backbone of
molecular biology. Since the middle of the 20th century, gene expression has been a
major focus in molecular biolgy research. Experiments are designed to monitor changes
in expression of an interesting gene in response to an internal or external stimulus and
these changes have furthered our understanding of how a protein functions in particular
biological pathways. As mentioned at the end of the previous section, genomic
sequencing has been useful to identify open reading frames that may code for genes
unique to a particular organism. However, measuring mRNA levels in cells can be highly
reflective of a gene’s influence on a cellular process such as proliferation, a major focus
o f this study. The methods used to study gene expression can be categorized as follows;
those methods that measure the expression of specific genes and those that analyze the
expression of hundreds or even thousands of genes simultaneously. While the assumption
has been that transcriptional changes are being measured by these methods, few methods
measure RNA synthesis directly. What is being measured are mRNA levels of particular
genes. This level is the sum of RNA transcription and RNA degradation rates. Nuclear
“run-on” transcription assays have been used to measure rates of transcription
(Gatehouse & Thompson, 1995). However, because of its complexity, this technique is
not often used. What follows is a description of some of the more popular procedures
that are being used to measure eukaryotic mRNA transcript levels.
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Northern and Dot Blotting
Because of its reliability and low cost, Northern blotting is one of the most
common techniques used to measure specific gene expression. This technique was first
described almost 30 years ago (Alwine, Kemp, and Stark, 1977). While some
improvements have been made over the years, the basic methods remain unchanged
(Sambrook, MacCallum, & Russell, 2001, Fernyhough, 2001). First, total RNA or
mRNA is resolved on denaturing agarose gels. Next, the RNA is transferred to and
immobilized on a solid matrix such as nitrocellulose or nylon membranes. Finally, the
RNA is hybridized with a labeled DNA or labeled anti-sense RNA probe. Excess probe is
removed by washing the membranes and the image of the hybridization product is
captured and analyzed. Historically, the probe has been labeled by the incorporation of
radioactive nucleotides and the membranes were exposed to x-ray film or scanned in a
phophor-imager. These exposed images can identify a transcript size and measure RNA
expression qualitatively. For quantification, membranes can be re-hybridized to internal
controls such as glyceraldehyde 3-phosphate dehydrogenase, beta actin and cyclophilin,
whose expression supposedly does not fluctuate greatly (Suzuki, Higgins, & Crawford,
2000; Weisinger, Gavish, Mazurika, & Zinder, 1999). Bianchi et al. used Northern
blotting in their studies on erythroid proliferation and differentiation. They showed that
tallimustine treatment inhibited human leukemic K562 cell proliferation and induced
erythroid differentiation as measured by increases in globin mRNAs (Bianchi et al.,
2001). In another study, Dai, Price, Brunner, and Krantz (1998) looked at the effect of
interferon gamma (IFN) on purified human erythroid colony-forming cells (ECFC). They
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found that the addition of IFN gamma inhibited growth and differentiation of ECFCs in a
time- and dose-dependent fashion. Accompanying these effects was a marked increase in
the percentage of cells expressing Fas on the surface of the ECFCs as well as the
intensity of Fas mRNA expression as measured by Northern blotting. Quite a few years
ago, we used Northern blotting to observe qualitative differences in certain ribosomal
protein mRNAs in wild type and mutant yeasts grown at the permissive and nonpermissive temperatures. Based upon the size differences and the resulting migration
patterns of these mRNAs, we determined a mutation existed that affected mRNA
splicing (Rosbash, Harris, Woolford, & Teem, 1980). While very powerful, Northern
blotting is limited in that it can be used for the identification of a small number of defined
gene transcripts. Also, since constitutive expression of the internal controls has not been
thoroughly studied, quantification results may be unreliable. Dot blotting is a similar, but
simpler hybridization method that has been used to quantitate mRNA. Rather than being
resolved on gels, RNA samples are “dotted” onto membranes directly (Sambrook et al.,
2001). Hybridization of the labeled probes to the immobilized RNA occurs as in
Northern blotting. Dot blotting can be used for quantification, but it cannot be used for
mRNA size determination. Another potential problem here is false-positive signals
resulting from DNA contamination. All DNA should be eliminated from the RNA sample
to avoid hybridization of the probe with genomic DNA. Tonini et al. (1987) used
Northern and dot blotting to study the modulation of c-myc expression in K562 cells
treated with certain anti-neoplastic drugs. These drugs blocked proliferation and induced
erythroid differentiation. They observed a short-term decrease in c-myc mRNA. At the
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time, they speculated that this transient decrease in c-myc expression is an initial event in
the differentiation of K562 cells.
Ribonuclease Protection Assay
The ribonuclease protection assay (RPA) is a sensitive and accurate method to
measure gene expression (Bader et al., 1992; Gilman, 2001). While it can be used to
measure the abundance of multiple mRNAs, in its simplest form, RPA is used to measure
expression o f a single target mRNA species in a complex mixture of total RNA purified
from cells (Mitchell & Fidge, 1996; Rottman, 2002). Briefly, the method involves the
hybridization of radio-labeled antisense RNA probes (riboprobes) to its complementary
target mRNA. The double-stranded RNA (dsRNA) hybrids are digested with single
stranded specific ribonucleases, RNase A and T. The remaining protected dsRNA
fragments are analyzed by electrophoresis on denaturing polyacrylamide gels and
subsequent autoradiography (Sambrook et al., 2001). If the riboprobe is in molar excess,
the intensity of the radioactive signal generated is directly proportional to the amount of
specific target mRNA in the original total RNA sample. The major advantages of RPA
are that multiple mRNA species can be measured simultaneously in a single total RNA
sample and that the assay has relatively high throughput. The major disadvantage is that
the assay requires moderate technical skill. Wang et al. (1997) studied the effects of
alpha thrombin on proliferation and differentiation of endothelial cells (EC). They used
RPA to measure changes in the expression of motility-related genes in human EC, and,
depending upon the type of human EC used, alpha thrombin exerted its chemokinetic
and mitogenic effects differentially.
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Primer Extension

Primer extension is a technique that is used primarily to map the 5’ end of
mRNAs, but it also can be used to quantify particular transcripts (Boorstein & Craig,
1989). Historically, early cloning methods often produced complementary DNAs
(cDNAs) missing the 5’ end o f the transcript. Primer extension was often used to identify
sequences involved in transcription and transalation initiation. As an example, Epstein et
al. (1986) used reverse transcriptase and a 49 nucleotide-long primer to reverse
transcribe rat RNA into cDNA. The size and sequence of this primer extension product
were analyzed on denaturing polyacrylamide gels, resulting in the identification of the 5’
end of rat parvalbumin mRNA. Gong, Alkhalf, Murphy, and Murphy (1992) used both
RPA and primer extension in studies of mitogenic signals in human endometrial
carcinoma cells. They showed that a phorbol ester enhanced transcription o f the calcyclin
gene from three identified transcription start sites (Gong 1992). While primer extension
is considered less sensitive than RPA, this gene expression technique is relatively easy to
implement, offers additional mRNA sequence information, and is more sensitive than
Northern blotting (Spira, 2005).

Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR)
One of the most sensitive and widely used methods in gene expression studies is
quantitative RT-PCR (Spira, 2005). This two-step method combines reverse
transcription (RT) with the polymerase chain reaction (PCR), a powerful technique for
which Kary Mullis (1990) won the 1993 Nobel Prize in chemistry. In the first RT step,
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cDNA is synthesized from mRNA using an RNA-dependent DNA polymerase. In the
second PCR step, using a special DNA polymerase (Taq polymerase) and cDNA-specific
oligonucleotide primers, multiple copies of the cDNA are made. Based upon the
thermostable properties of Taq polymerase, thermal annealing properties of nucleic
acids, and the reaction cycling temperatures, the amount of cDNA can be amplified
logarithmically.
The amplified cDNA can be viewed and analyzed on non-denaturing
polyacrylamide or agarose gels. Because of the incredible power to amplify the DNA,
problems such as contaminating DNA, may arise. However, with the inclusion of
appropriate internal or external standards, these problems can be minimized and
transcript levels quantified (Freeman, Walker, & Vrana, 1999). As with many other
molecular biology techniques, commercial enterprises have made improvements to RTPCR. With the discovery and implementation of molecular beacons (fluorescent probes),
Taqman RT-PCR is a commercial method that has surpassed RT-PCR for transcription
quantitation (Yin et al., 2001). This method, which is used in this study, relies on specific
hybridization probes containing a fluorescent dye (fluorophore) at one end and a
quenching dye at the other end. When free in solution, the probes’ ends are in close
proximity to one another, such that the fluorescent dye is quenched. At the beginning of
the PCR reaction, the primers and probes anneal to the target cDNA. During DNA
polymerization, Taq polymerase’s exonuclease activity hydrolyzes the probe and the
flourophore is released. The detected fluorescence is proportional to the amount of PCR
product that is being produced (Bustin, 2000). This cumulative fluorescence provides a
kinetic measure of DNA amplification and is a more precise measure of mRNA levels
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than RT-PCR. However, successful application of Taqman RT-PCR requires an
understanding of the practical problems, such as DNA contamination, and a careful
experimental design of primers and probes. As with the other methods, proper validation
is essential for precise mRNA quantitation. Combined with microarray studies (see
below), RT-PCR techniques have been used to study gene expression changes resulting
from chemotherapeutic treatments. Using microarrays, Lehnhardt et al. (2005) analyzed
the expression patterns displayed in H T1080 fibrosarcoma cells treated with several
chemotherapeutic agents. Using RT-PCR, they validated the expression of 46 candidate
genes. Closer analysis of these differentially regulated transcripts revealed that
doxorubicin induced cell death by influencing the abundance of factors mediating the
mitochondrial (intrinsic) apoptosis pathway. Despite being able to measure one transcript
per reaction, Taqman RT-PCR can be automated and made somewhat high throughput.
Nevertheless, because reagents and the equipment to measure fluorescence are rather
expensive, Taqman RT-PCR is being used more in well-funded and commercial
laboratories.
Differential Display Reverse Transcription-Polymerase Chain Reaction (DD RT-PCR)
Primarily, there are three methods that are used to measure expression changes in
numerous genes simultaneously. DD RT-PCR, the first technique, was invented in 1992
and has been used to identify changes in large subsets of known and unknown mRNAs
(Liang & Pardee, 1992; Liang, Averbouhk, & Pardee, 1994). Currently, DD RT-PCR
uses oligo-dT primers in combination with a series of arbitrary 13-mer oligonucleotides
to reverse transcribe (RT) and amplify (PCR) mRNAs from treated and control cells.
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These amplified cDNA copies can then be separated and displayed on gels, providing a
pattern of differentially expressed genes. GenHunter, a company in Nashville, Tennesee
that markets DD RT-PCR products, advertizes that there have been more than 3500
citations using DD RT-PCR during the last 14 years (http://www.genhunter.com/). This
method has been especially useful for studying the effect of drugs or xenobiotics on gene
expression. While this method can be used to estimate differences in gene expression, the
major advantage to DD RT-PCR is that it can be used to identify new and novel genes.
In 1996, we used this technique to identify four transcripts whose expression is altered in
dioxin-treated hepatoma cells (Wang, Harris, Ulrich, & Voorman, 1996). We showed
and confirmed by Northern blotting that dioxin decreased fibrinogen gamma and plastin
mRNA levels in a time-dependent manner; whereas, it increased two unidentified
transcripts. Decreases in fibrinogen and plastin suggest that dioxin may play a role in
hemostasis and tumorigenesis, respectively. Recently, from sequence similarity searches
we have performed, one of the increased transcripts from this study is very similar to a
human ribosomal protein L7-like 1 mRNA, accession # BC064519. This result suggests
that dioxin may have effects on protein synthesis apparatus (Strausberg et al., 2002).

Serial Analysis of Gene Expression (SAGE)
SAGE is a second method for a comprehensive analysis of gene expression
patterns. The method is broadly applicable for the quantitation and comparison of
expressed genes in a variety of normal, developmental, and disease states (Porter, Yao,
& Polyak, 2006; Velculescu, Zhang, Vogelstein, & Kinzler, 1995; Yamamoto,
Wakatsuki, Hada, & Ryo, 2001). The SAGE procedure has three underlying principles:
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1. Short DNA sequence tags (10-14 base pairs in length) contain enough information to
uniquely identify a transcript. 2 . Short sequence tags can be linked together. 3. The
frequency of a particular tag correlates to the expression level of the corresponding
transcript. In the SAGE protocol, the first step is the synthesis of cDNA using RT and a
biotinylated oligo-dT primer. Next, the cDNA is digested with a four base pair cutter
restriction endonuclease called the anchoring enzyme. The digestion products are
immobilized on streptavidin-coated beads and then divided. Each half is ligated to a
different DNA linker that binds to the cohesive ends previously created by the anchoring
enzyme. Each linker contains a type IIS restriction site (asymmetric recognition
sequences) and a unique priming sequence. Upon digestion with the type IIS restriction
endonuclease, DNA fragments are released from the beads. These small DNAs are
enzymatically blunt-ended and ligated together creating “ditags.” Using PCR primers to
the unique sites within the linkers, the ditags are amplified. Following the PCR
amplification step, the ditags are digested with the anchoring enzyme to release the
linkers. The ditags are then ligated in tandem and cloned into a plasmid vector used for
sequencing. Because the tags are short, about 50 tags can be read per sequencing
reaction. Finally, the repeat sequences are counted and searched for homology versus
known DNA sequences. Menssen and Hermeking (2002) used SAGE in an attempt to
identify target genes of the oncogenic transcription factor c-MYC. In primary human
umbilical vein endothelial cells, in which cMYC was over-expressed, 216 unique mRNAs
were induced, while 260 mRNAs were repressed. Transcript levels were confirmed on
53 genes using RT-PCR and microarray analysis. They concluded that the c-MYCregulated genes/tags identified will help to define the set of bona fide c-MYC targets and
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may have potential therapeutic value for inhibition of cancer cell proliferation, tumorvascularization, and restenosis (Menssen & Hermeking, 2002). While the SAGE
procedure is quite labor intensive, requiring a multitude of reactions, there are some
advantages to this technique. One advantage is that SAGE is a counting-based method.
Rather than relying on hybridization thermodynamics for transcript level determinations,
the abundance of a transcript is assessed by counting the number of sequence tags
representing that transcript relative to the total number of tags identified. Thus, the
proportion of one transcript relative to another can be determined directly. Also, SAGE
requires no a priori sequence information. As in DD RT-PCR, differential expression of
yet unidentified genes can be detected.
DNA Microarrays
The third and newest technique for studying patterns of expression for numerous
genes is DNA microarrays. Two recent advances, gene identification through massive
DNA sequencing efforts, such as the human genome project, and the technical ability to
immobilize orderly these gene sequences on solid silicon supports, have pushed this
technique into the mainstream, or perhaps forefront, of molecular biology research
(Venter et al., 2001; Pease et al., 1994). The basic principle of the technique involves
hybridizing labeled cDNAs made from target RNAs to gene-specific DNAs that have
been spotted onto glass slides (microarrays). Primarily, there are two types of microarray
platforms in use today. The cDNA microarray, developed by Brown and colleagues in
1996, involves depositing PCR-amplified cDNAs onto a glass slide using a robotic
spotting device (Shalon, Smith, & Brown, 1996). Sample RNAs are then converted into
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cDNA into which fluorescent dyes Cy3 or Cy5 have been incorporated. Flourescent
sample (experimental) cDNAs and reference (control) cDNAs labeled with another fluor
are mixed and hybridized to the same DNA microarrays. Measuring and comparing the
sample fluorescent signal intensities relative to the reference signal intensities can
determine the abundance of each transcript in each sample. In the case of oligonucleotide
microarrays, either gene specific oligonucleotides are spotted onto or synthesized in situ
on glass slides (Lockhartet al., 1996; Hughes et al., 2001). Today, perhaps the most
widely used oligonucleotide microarray platform is the one commercially available from
Affymetrix, Santa Clara, CA. The microarray (chip) contains gene-specific
oligonucleotide probes that are photolithographically synthesized onto glass. In addition,
probes containing a mismatch at the central position are included as controls for cross
hybridization. Sample RNAs are converted to cDNA, from which phycoerythrin-labeled
cRNA is prepared. Next, the labeled test and control cRNAs are hybridized to separate,
but identical, micorarrays. Binding is detected by staining with a fluorescent dye coupled
to streptavidin. Laser-captured signal intensities are used to measure the relative cRNA
abundance for the genes represented on each microarray. To obtain differential
expression results, sophisticated computer programs compare and analyze the signal
intensities on both microarrays. With the ability within one experiment to measure
changes in expression of complete genomes, whole new areas of molecular biology have
been augmented. Pharmacogenomics examines how one’s genetic makeup affects a
person’s response to drugs. Microarrays can be used to determine the effects of a drug
on global transcription. In so doing, key genetic biomarkers may be identified and used in
evaluating a drug’s effect in the overall population. For an example of how microarrays
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are furthering this area of research, researchers from Washington University School of
Medicine in St. Louis, Missouri discussed “clinically relevant gene polymorphisms that
influence the outcome of cancer therapy, and whole-genome expression studies using
microarray technology that have shown tremendous potential for benefiting cancer
pharmacogenomics” (Watters & MacLeod, 2003). More fundamentally, scientists are
using microarrays to further classify tumors based upon the gene expression patterns.
This classification may help in building a more focused treatment regimen. In the realm
of toxicology and toxicogenomics, researchers are using microarrays to focus their
analysis on the basic questions of how chemicals and drugs induce disease in normal cells
or tissues (De Longueville, Bertholet, & Remade, 2004). Bulera et al. (2001) used
microarrays to analyze the expression pattern in liver from Wistar rats treated with six
known hepatotoxicants. This analysis identified multiple genes and groups of genes that
were affected by the six hepatotoxicants, indicating that high-density microarray
expression data are useful to identify groups of genes involved in toxicity. Further, to
support the use of microarrays to determine or predict toxic liver effects, the identity of
an unknown sample was revealed by comparing its expression pattern profile with the
compiled expression profiles from the known hepatotoxicants (Bulera et al., 2001).
While the microarray technology is becoming more and more popular, it is not without
problems. First, microarray technology is very expensive. Not only are the microarrays
themselves quite expensive to produce, the laser detection system, microarray wash
station, and accompanying computer equipment costs put this technology out of reach
for most molecular biology labs. Further, there have been some basic concerns raised
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over microarray reproducibility and standardization (Bammler et al., 2005, Waring et al.,
2005).
We chose to use Asymetrix microarray technology to study the effects of
chloramphenicol on gene expression in mammalian cells and confirmed these changes by
Taqman RT-PCR. Because all mammalian cells contain mitochondria, we hypothesize
that myeloid cells contain other factors, such as uniquely expressed genes, that make this
tissue perhaps more sensitive to this antibiotic than other tissues. Leiter et al. (1999)
have examined the effects of chloramphenicol on mitochondrial function in K562 cells, a
human erythroleukemia cell line frequently used to study red blood cell precursors. In
this work, it was shown that chloramphenicol inhibited oxidative metabolism, reduced
the activity of cytochrome c oxidase (COX), and lowered the ATP content of the cells.
In addition, this antibiotic reduced the production of the ferritin and the transferrin
receptor. The reduction of these two proteins was somewhat surprising, since eukaryotic
ribosomes in the cytosol are the sites of synthesis of these two iron-related proteins.
Interestingly, using Northern blotting, they showed that chloramphenicol decreased only
the mRNA levels for the transferrin receptor. Though it was unclear how the
chloramphencicol-induced mitochondrial dysfunction caused a decline in these two
important proteins in heme homeostasis, since total cellular protein synthesis was
unaffected by this treatment in these cells, a link was established between the
mitochondria and these two particular proteins. The goal of this study will be to see if
global transcriptional changes in cells treated with choramphenicol can identify genes
whose expression correlates with effects on proliferation. It is proposed that we examine
global transcriptional changes resulting from chloramphenicol treatment to see if these

Reproduced with permission o f the copyright owner. Further reproduction prohibited without permission.

34
events can be separated in any way from its known effects on mitochondria and
proliferation.
Cell Model for Studying Effects of Chloramphenicol on Hematopoietic Cells
To study the effects of chloramphenicol on cells, we chose to study proliferation
and gene expression changes in a murine erythroleukemia cell line. Since
chloramphenicol has an effect on red blood cell number, a cell culture system that
enables the study of erythroid progenitors is a useful and convenient tool for assessment
of the effects of antibiotics on hematopoiesis. The cells used in this work are related to
erythroleukemia cells first characterized by researchers back in the 1950s. Using electron
microscopy, Charlotte Friend and Cecily Selby (1954), colleagues at Sloan-Kettering in
New York, noticed that cells from Ehrlich carcinoma had cytoplasmic particles that were
similar to those seen in thin-sections of virus-infected cells. Charlotte Friend decided to
inoculate newborn mice with cell-free extracts from this cancer. While these mice
appeared visibly healthy, upon being sacrificed and examined, several of the mice
contained enlarged spleens. After Friend injected spleen cells from these mice into adult
mice, several animals obtained palpable spleens. Soon Friend was able to show that the
disease she was seeing was unique. This cancer was characterized by erythroblastosis
and a profound anemia. Besides being transmissible in adult non-inbred mice, the short
latent period before the first symptoms appeared was powerful evidence that the
transmissible agent was directly involved in the induction of the leukemia (Friend, 1956).
Later Friend demonstrated that in some instances, expression of the malignant phenotype
could be reversed experimentally. Upon treatment of some of the erythroleukemia cells
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with DMSO, she was able to inhibit cell proliferation and induce differentiation as
measured by increases in cellular hemoglobin production (Friend, Scher, Holland, &
Sato, 1971). For this work, the virus and leukemia now bear Friend’s name. The Friend
erythroleukemia cells became a widely used model for studying control of erythroid
differentiation, as well as malignant transformation and disease (Ruscetti, 1995; Lee et
al., 2003).
The cell line we used in this work is derived from a leukemia induced by a Btropic Friend leukemia virus (ATCC TIB-55 BB 88 , Chesebro, Wehrly, & Housman,
1978). While there are several strains of erythroleukemia viruses, the B-tropism here
refers to the ability of this particular retrovirus to grow preferentially in BALB strain
mice cells. This growth property is regulated by a single genetic locus, Fv-1; such that Btropic Friend retroviruses can integrate only into host DNA containing the permissive
F v-lb/bgenotype. The result of this integration is that the cells appear to be blocked at the
colony-forming cell for erythropoiesis (CFU-e) stage of erythropoiesis. This block is
caused primarily through the interaction of a unique viral envelope protein and the
erythropoietin (Epo) receptor that results in receptor activation and subsequent erythroid
signaling (Ruscetti, 1999). The aberrant receptor activation causes cell proliferation and
differentiation in the absence of Epo, an essential regulator of erythroid cells (Richmond,
Chohan, & Barber, 2005). These cells and other murine erythroleukemia (MEL) cells
have been used in a variety of studies examining changes in gene expression as a result of
differentiation induction (Gambari, Marks, & Rifkind, 1979; Karacay & Chang, 1999;
Klinken, Holmes, Morse, & Thorgeirsson, 1988; Obinata, Kameji, Uchiyama, &Ikawa,
1978; Profous-Juchelka, Reuben, Marks, & Rifkind, 1983; Zaker, May, & Burnett,

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

36
2002). In addition, they have been used to show that compounds that inhibit MPS also
hinder erythroid maturation as measured by hemoglobin accumulation in chemicallyinduced MEL cells (Kaneko, Watanabe, & Oishi, 1988). An objective of this study is to
measure the effects of chloramphenicol in proliferating BB 88 MEL cells.
Chloramphenicol and Its Toxicity
In 1947, Chloramphenicol (Chloromycetin) was first isolated from an
actinomycete, Streptomyces venezuelae. This organism had been found in a soil sample
obtained from a field near Caracas, Venezuela (Ehrlich, Bartz, Smith, Joslyn, &
Burkholder, 1947). In sensitive bacteria, chloramphenicol is a potent and specific
inhibitor of protein synthesis. The mechanism of this inhibition is attributed to its
stereospecific and reversible binding to the 50S ribosomal subunit (Cundliffe 1967;
Lorian, 1971). In particular, chloramphenicol has been shown to bind preferentially to
bacterial protein LI 6 of the 50S subunit. This binding prevents the attachment of the
amino acid containing end of the amino-acyl t-RNA complex to the ribosome and thus,
inhibits peptide bond formation (Pongs, Bald, & Erdmann, 1973). Nucleotide
footprinting studies identified that chloramphenicol interacts strongly with nucleotides
Adenosine-2451 and Guanine-2505, sites within the peptidyl transferase region on 23 S
rRNA. This interaction bolstered chloramphenicol’s influence in peptide translation
inhibition (Moazed & Noller, 1987).
With great excitement and fanfare, chloramphenicol was approved in 1949 for
distribution in the United Sates (Maeder, 1994). While this antibiotic showed great
promise for treating a number of infections such as typhoid fever and meningitis,
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chloramphenicol treatment was not without problems. Microbial resistance can and does
occur (Calder 1972; Friedland & Klugman, 1992; Jorgensen, 1991; Linares, Tubau, &
Dominguez, 1999; Scott et al., 2005). Primarily, this resistance is the result of a specific
plasmid that causes the production of acetyltransferases. These transferases acetylate
chloramphenicol so that it no longer binds to bacterial ribosomes (Gaffney, Foster, &
Shaw, 1978; Shaw & Brodsky, 1967; Shaw, 1971). However, it was not
chloramphenicol resistance that created the most controversy, as resistance occurs to
most, if not all, antibiotics. It was the adverse effects chloramphenicol was having on
patients’ myeloid tissue that created the biggest problem for this medicine.
Two types of myelotoxicity have been linked to chloramphenicol usage. The
most serious toxicity is idiosyncratic aplastic anemia. Death from aplastic anemia has
been estimated to occur in one of 20,000-40,000 courses of chloramphenicol treatment.
(Smick, Condit, Proctor, & Sutcher, 1964; Feder, Osier, & Maderazo, 1981) and while
this type of anemia is quite rare, it is irreversible and most often fatal. To date, the
mechanism by which chloramphenicol causes aplastic anemia remains elusive. Some
researchers have suggested genetics may be involved in human chloramphenicol-induced
aplastic anemia (Dameshek, 1969). Others have suggested that aplastic anemia is
associated with the DNA damage caused by nitroso-chloramphenicol (Yunis, Miller,
Salem, Corbett, & Arimura, 1980). Nitrosochloramphenicol is a product of the metabolic
reduction of the para nitro group of chloramphenicol and the ability to perform this
reduction may be genetically determined. Also, Skolimowski, Knight, and Edwards
(1983) showed that thiamphenicol, a compound with similar antimicrobial properties to
chloramphenicol, but whose structure lacks the para nitro group, did not cause DNA
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damage in mammalian cells in vitro. While it does affect myeloid tissue, there have been
no definitive cases o f aplastic anemia attributed to thiamphenicol (Yunis, 1981).
Unfortunately, very little of this work can be corroborated by in vivo experiments
(Turton et al., 2000). To date, there have been no successful animal models that link
aplastic anemia to chloramphenicol treatment (Festing, Diamanti, & Turton, 2001; Chen,
2005). Nevertheless, the threat of aplastic anemia has caused a dramatic decline in
chloramphenicol’s usage in the United States and the pharmaceutical company Parke
Davis (now Pfizer, Inc.) has not manufactured this antibiotic for over 25 years.
The second and most common type of myelotoxicity accompanying
chloramphenicol therapy is dose-related and reversible bone marrow suppression (Erslev
1953; Yunis, 1988). Therapeutically relevant concentrations of chloramphenicol affect
cell growth of a variety of mammalian cells (Firkin & Linnane, 1968; Holt, Ryder,
Fairbairn, Hurley, & Harvey, 1998; Kang et al., 2005). This anti-proliferative effect
appears to be as a result of MPS inhibition both in vitro and in vivo (Bread, Armentrout,
& Weisberger, 1969; Fettes, Haidar, and Freeman, 1972; Kroon & Van Den Bogert,
1983; Martelo, Manyan, Smith, and Yunis, 1969; Summ, Draeger, and Von
Wasielewski, 1976). In a related finding, Nagiec et al. (2005) have shown that the
oxazolidinones, a new class of chemicals that inhibit bacterial and MPS by binding to a
similar ribosomal site, also inhibit K562 human erythroleukemia cellular proliferation
reversibly. Further, cells depleted of their mitochondrial DNA by ethidium bromide
treatment were unaffected by the oxazolidinones (Lin, Murray, Vidamr, & Marotti,
1997; Nagiec et al., 2005). Reversible myelosuppression and thrombocytopenia was
seen in patients receiving Linezolid, an oxazolidinone approved for marketing in 2000
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(Attassi, Hershberger, Alam, & Zervos, 2002; Green, Maddox, & Huttenbach, 2001;
Paladino, 2002; Waldrep & Skiest, 2002). While, the pathogenesis of this
myelosuppression appears related to the antibiotic’s effect on mitochondria, it is unclear
why myeloid tissue is so vulnerable. Because mammalian cells depend upon
mitochondrial function for energy and the toxic effects of chloramphenicol appear
primarily in the bone marrow, there may be other factors involved. Some have argued
that cellular sensitivity may be the result of a cell’s respiratory “threshold capacity”
(Rossignol et al., 2003). A high threshold capacity in a tissue means a greater loss in
mitochondrial proteins can be sustained, without losing mitochondrial function. Perhaps
erythroid tissue has a low threshold capacity whereby losses in mitochondrial protein
brought on by chloramphenicol treatment, dramatically affect respiration.
To better understand chloramphenicol’s anti-proliferative effects on erythroid
tissue, experiments to examine transcriptional changes in a cell model of this tissue were
initiated. This report describes the application of DNA microarray technology to
measure changes in gene transcript levels in BB 88 erythroleukemia cells. Because all
cells contain mitochondria, we hypothesize that myeloid cells contain other factors, such
as uniquely expressed genes, that make this tissue perhaps more sensitive to this
antibiotic than other tissues. As has been mentioned earlier, Leiter et al. (1999) have
examined the effects of chloramphenicol on mitochondrial function in K562 cells, a
human erythroleukemia cell line frequently used to study red blood cell precursors. In
this work, chloramphenicol treatment not only inhibited oxidative metabolism and ATP
production, but also reduced the amount of certain proteins involved in iron homeostasis.
Interestingly, Northern blotting showed that chloramphenicol decreased mRNA levels
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for only one of the proteins, the ferritin receptor, suggesting that chloramphenicol affects
genes differentially. From these results, the investigators concluded that the previously
unsuspected link between mitochondrial function and cellular iron metabolism might
contribute to the anemia that often develops even in the absence of sideroblastic changes
in the bone marrow. In a more recent study using K562 cells, Kang et al. (2005) show
that longer-term chloramphenicol treatment (6-9 days) induces apoptotic cell death
through a caspase-dependent pathway presumably by suppressing the expression and
protein levels of certain cell cycle regulatory molecules. Our effort in this study will be to
see if global transcriptional changes in a murine erythroleukemia cells (BB 88) treated
with choramphenicol can identify genes whose expression correlates with effects on
proliferation. We propose to examine global transcriptional changes resulting from
chloramphenicol treatment to see if these events can be separated in any way from its
known effects on mitochondria and proliferation. By looking at early effects (24 hours)
of chloramphenicol, we predict that transcription changes in these cells will be uniquely
tied to the mitochondria, a primary toxic target for this and other similar antibiotics
(Nagiec, 2005). Studying transcriptional changes may be useful in identifying not only
cellular changes induced by chloramphenicol, but also a particular antibiotic marker of
chloramphenicol toxicity.
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MATERIALS AND METHODS
Chemicals, Reagents, and Compounds
Chemicals and reagents were purchased from Sigma (St. Louis, MO), Boehringer
Mannheim (Indianapolis, IN), Invitrogen (Carlsbad, CA), and Applied Biosystems, Inc.
(ABI, Foster City, CA), unless specified. Chloramphenicol (MW 323.1) was purchased
from Boehringer Mannheim (#634-433). Chloramphenicol was dissolved in ethanol
(EtOH) to 100 mM and used at 50 pM final concentration unless specified. PNU-86983
and PNU-78714 were obtained from Pharmacia's (Pfizer) Research Compound
Collection. 100 pM stocks were prepared by dissolving these compounds in DMSO
(Sigma D-2650). Similarly, a 100 pM stock solution of Tetracycline (Sigma T- 8032) in
water was prepared. Erythromycin (Sigma E-6376), oligomycin (Sigma 0-4876), and
succinylacetone (Sigma D-8645) stock solutions were prepared by dissolving
compounds in DMSO. These stock solutions were stored at -20° C. The antibiotic
Geneticin (50 mg/ml) (Invitrogen #10131035) was stored at 4° C. Oligonucleotide
primers and probes were designed using Primer Express version 2.0 software (ABI,
Applied Biosystems, Inc. Foster City, CA) and these oligonucleotides were synthesized
by ABI or Sigma-Genosys (Woodland, TX).

41
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Cell Culture
BB 88 murine erythroleukemia cells (ATCC TIB 55) were maintained in RPMI
1640 medium (with L-glutamine) (Invitrogen # 11875-093), containing 10% heatinactivated fetal bovine serum (Invitrogen #10082-139), 10 pM 2-mecaptoethanol
(PME)(Aldrich M370-1), and Penstrep antibiotic (Invitrogen #15140-122) (5 ml per 500
ml of medium). Cells were seeded at approximately 2 x 104 cells per milliliter (cells/ml),
maintained in 5% CO2 at 37° C, and split after 5-6 cell doublings (-12 hours per
doubling). Cell counts were determined using a Coulter Counter ZM (Beckman-Coulter
Inc.). Compounds were added to cells to a final diluent concentration of 0.1% v/v.
Total RNA Isolation
RNA was isolated from BB 88 cells using Trizol (Invitrogen #15596-026).
Briefly, cells were pelleted by centrifugation at 500 x g in a Sorvall RT6000B centrifuge.
Cell pellets were resuspended in Trizol (1 ml per 106cells). Nucleic acids were extracted
with CHCI3 and phenol and precipitated using EtOH following the procedures described
in the Trizol package insert. RNA pellets were dissolved in DNAse/RNAse-free water
(Invitrogen #10977-015) and quantitated using spectrophotometry (Genequant,
Pharmacia Biotech). Residual DNA was removed by passing RNA aliquots (100
micrograms (pg)) over RNeasy mini columns (Qiagen #74106). Briefly, immobilized
RNA was treated for 15 minutes at room temperature with DNAse 1 (Qiagen #79254),
washed with the kit’s RW1 buffer (Qiagen #74106), and eluted with water. Total RNA
was quantitated spectrophotometrically (1 Optical Density unit at 260 nanometers for
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RNA molecules equals 40 nanograms (ng) per microliter (pi) of RNA) and analyzed for
fidelity (DNA contamination and/or degradation) using an Agilent Bioanalyzer, see
Figure 5.

L 1 2 3 4 5 6 7 8

MM HhM

Figure 5. Agilent Bioanalyzer Analysis of BB 88 RNA.
One microliter aliquots of DNAsed and Qiagen column-purified RNA (100 ng) were
loaded into wells on the RNA LabChip (Agilent Technologies). Wells containing RNA
and buffer, as well as RNA standards (L) and buffer, were mixed. The chips were loaded
into and run through the bioanalyzer instrument. Lanes: L- RNA ladder (Agilent RNA
6000 Nano Ladder, 6000, 4000, 2000, 1000, 500, and 200 nucleotides), 1-2, Control
RNAs 0 hours, 3-5 Control (0.1% ethanol) RNAs 24 hours, 6-8 Treated (50 pM
chloramphenicol) RNAs 24 hours. Ribosomal RNAs, 28S and 18S, are marked by
arrows.
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cDNA Synthesis and Labeled cRNA Preparation
To prepare double-stranded cDNA (ds-cDNA) and biotin-labeled cRNA for
micrroarray chip hybridizations, the procedures described in the year 2000-GeneChip
Expression Analysis Technical Manual were followed (Asymetrix, Santa Clara CA,
Bammert 2000). Using components from a Custom Superscript Double-stranded cDNA
Synthesis Kit (Invitrogen #11917-010), ds-cDNA was prepared from a mix of 7.5 pg
total RNA and 100 picomoles of a T7-modified oligo-dT primer (GENSET Corporation,
La Jolla, CA, cat. #GUAR10) in a final volume of 150 pi. This two-step reaction was
extracted with an equal volume of phenol '.CHCLs: isoamyl alcohol, and the organic and
aqueous layers were separated using Phase Lock Gel I-Light matrix (5 Prime, Inc. #pl188233). The aqueous layer was transferred to a DNAse/RNAse-free 1.5 ml
microcentrifiige tube and precipitated using ethanol ammonium acetate in the presence of
glycogen (5 pg) (Ambion #9510). Next, a commercial in vitro transcription kit (Enzo
#900182) was used for preparing biotin-labeled cRNA. Briefly, 10 pi cDNA aliquots
were combined with 30 pi of a proprietary in vitro transcription reaction mix, containing
hybridization buffer, biotin-labeled ribonucleotides, dithiothreitol (DTT), RNase inhibitor
mix, and T7 polymerase. After incubation for 4.5 hours at 37°C (tubes were mixed gently
every 30 minutes), each reaction was passed over an RNeasy mini column and labeled
RNA was evaluated spectrophotometrically, see above.
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Fragmentation of Labeled cRNA and Target Hybridization

In a total reaction volume of 30 gl, 15 gg cRNA aliquots were mixed with 6 gl
o f 5x Fragmentation Buffer (200 mM Tris acetate, pH 8 .1, 500 mM potassium acetate,
150 mM magnesium acetate). After heating the mixture for 35 minutes at 94° C, this
cRNA Target was stored at -20° C until hybridization. Using the Affymetrix Gene Chip
Protocol and the GeneChip Eukaryotic Hyrbridization Control Kit (Affymetrix #
900299), the cRNA Target Hybridization Mix was prepared as shown in Table 1.
Table 1. Reaction Components for Typical cRNA Target Hybridization Mix
Component

Volume (gl)

Final concentration

cRNA Target

30

0.05 gg/gl

3nMControl01igoB2*

5

50pM

20x Eukaryotic Hybridization Controls**

15

Varied**

Herring Sperm DNA 10 mg/ml
(Invitrogen)

3

0.1 mg/ml

Acetylated BSA 50 mg/ml (Invitrogen)

3

0.5 mg/ml

2x Hybridization Buffer***

150

IX

water

94

Final

300

* Control Oligo B2 - Affymetrix synthetic control oligo used for alignment signals
** 20x Eukaryotic Hybridization Controls - Affymetrix mixture of 30 pM bioB(BIOB),
100 pM bioC(BIOC), 500 pM bioD (BIODN), and 2000 pM ere (CREX) cRNA Target
controls. Heat separately at 65° C for 5 minutes before adding to mix.
**'* 2x HybridizationBuffer - (final lx concentration is: 100 mM MES, pH 6 .6 , 1 M
NaCl, 20 mMEDTA, 0.01% Tween 20).
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Each cRNA target hybridization mix sample was heated to 99° C for five
minutes, then incubated at 45° C for five minutes, followed by a five minute
centrifugation at maximum speed (10,000 x g) to remove any insoluble material. During
these incubations and centrifugation steps, each U74Av2 microarray (Affymetrix #
900343) was pre-wetted with 200 pi of lx Hybridization Buffer (see above). Next, the
lx Hybridization Buffer was replaced in each microarray with 200 pi of cRNA Target
Hybridization Mix. All microarrays were incubated for 16 hours at 45° C in a rotisserie
oven (Affymetrix GeneChip Hybridization Oven 640).
Microarray Washing and Staining
After 16 hours, cRNA Target Hybridization mixes were removed from the
individual microarrays and replaced with 200 pi of Non-Stringent Wash Buffer (6x
SSPE, 0.01% Tween 20, 0.005% Antifoam (Sigma A-8082)). While the Affymetrix
Genechip Fluidics Station was readied for the washing and staining steps, the
microarrays were set aside and the Hybridization Mixes were stored at -20° C. The
Fluidics Station reservoirs were filled with freshly-prepared Stringent Wash (100 mM
MES pH 6 .6 , 100 mMNaCl, 0.01% Tween 20 (Pierce #28320) and Non-Stringent Wash
Buffers (see above). To stain and amplify the hybridized cRNA Target on each
microarray, two solutions, Antibody Amplification Solution (Ab) and Streptavidin
Phycoerythrin Stain Solution (SAPE), were prepared as shown in Tables 2 and 3.
Next, the Fluidics station was primed and programmed to perform the EukGEWS2v4 protocol (Affymetrix Microarray Suite User’s Guide Version 5.0). This protocol
included a series of steps that included a SAPE staining, an Ab amplification, and a
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Table 2. Reaction Components for the Antibody Amplification Solution (Ab)
Volume (pi)

Final concentration

2 x Stain Buffer (200 mM MES pH 6 .6 , 2 M
NaCl, 0.1% Tween 20, 0.01% Antifoam)

300

1X

Acetylated BSA (50 mg/ml)

24

2 mg/ml

Goat IgG (10 mg/ml) (Sigma 15256)

6

0.1 mg/ml

3.6

3 pg/ml

Reagent

Anti-streptavidin antibody (0.5 mg/ml)
(Vector Laboratories BA-0500)
water

266.4

Final

600

Table 3. Reaction Components for the Streptavidin Phycoerythrin Stain Solution (SAPE)
Volume (pi)

Final concentration

2x StainBuffer

600

lx

Acetylated BSA (50 mg/ml)

48

2 mg/ml

R-Phycoerythrin Streptavidin (1 mg/ml)
(Molecular Probes # S-866)

12

10 pg/ml

Reagents

water

540

Final

1200

second SAPE staining. Stringent and non-stringent washes accompanied each of these
staining and amplification steps, see the Affymetrix Microarray Suite User’s Guide
Version 5.0. Following washing and staining, each microarray was scanned on the
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Affymetrix scanner. All o f the scanned values were imported automatically into the
Affymetrix Microarrary Suite 5.0 gene expression analysis software.
Transcript Analysis Algorithm
Affymetrix microarrays consist of oligonucleotides synthesized and bound in situ
to a 24 x 24 micron Probe Cell using photolithography (Pease et al., 1994). Each ORF
(open reading frame) is represented by a Probe Set. Probe Sets consist of approximately
twenty oligonucleotide pairs. Each oligonucleotide (20-mer) pair consists of an oligomer
(PM-perfect match) that is designed to match the ORF sequence and an oligomer (MMmismatch) that contains a homomeric mismatch in the middle of its sequence. A single
intensity value for every Probe Cell, representative of the hybridization signal of its
cRNA Target, is measured, and then corrected for background across the entire array,
(see Appendix C in the Affymetrix Microarray Suite 5.0 User’s Guide). Probe Cell
intensities, both PM and MM, are used to determine the Signal. The Signal is a
quantitative metric calculated from each Probe Set, which represents the transcript
amount in solution (RNA sample). The Signal is calculated using the one-step Tukey’s
Biweight Estimate algorithm, yielding a robust weighted mean. To obtain this mean,
each probe pair in a probe set potentially has a vote in the Signal value determination.
The vote is an estimate of the real signal due to hybridization of the target cRNA. This
real signal is estimated by taking the log (PM intensity minus the MM intensity). The
Probe Pair vote is weighted more strongly if its real signal value is closer to the median
value for an entire Probe Set. Next, a mean of the weighted intensities for a Probe Set is
identified. This mean is corrected back to the linear scale and the Signal is its output. For
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more details on Signals, (see Appendix C in the Affymetrix Microarray Suite 5.0 User’s
Guide and /or Affymetrix’s GeneChip Expression Analysis - Data Analysis
Fundamentals guide [available online at www.Affymetrix.com]).
Before comparing two microarrays, Signals were normalized by scaling. Scaling
helps correct for variations between any two arrays. Biological and technical differences
are two of the major sources of variation in any array experiment. Biological differences
may include such things as time and treatment differences, while technical variation may
be due to experimental variables such as the quality and quantity of target hybridized,
staining, and handling error. In scaling, each Signal value on a particular array is
multiplied by a scaling factor (SF) to make the average intensity of all of the signals on
that microarray equal to an arbitrary user-defined average target threshold (TGT). Not
only does this permit comparison of microarray data within an experiment, but also
comparison of microarray data between experiments.
Two algorithms within Affymetrix Microarray Suite 5.0 GeneChip Comparison
Analysis software are used to compare probes sets on one (experimental) array to their
counterparts on another (baseline) array. To determine the magnitude and direction of a
change in a transcript, the Signal Log Ratio (SLR) is computed. Similar to the Signal
algorithm, the SLR is computed using a one-step Tukey’s Biweight method by
calculating the mean of the log2 ratios of probe pair intensities between any two arrays.
The Wilcoxon’s Signed Rank test uses the differences between PM and MM intensities,
as well as the differences between PM intensities and background to compute three, one
sided p-values. The most conservative value of the three is recorded and represents the
Change p-value, Appendix B. Values close to 0.5 signify there has been no change in the
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transcript level between experimental and baseline arrays, whereas values closer to 0
represent transcripts that have increased (Inc) or marginally increased (MI) while values
close 1.0 represent transcripts that have marginally decreased (MD) or decreased (Dec).
(Affymetrix’s GeneChip Expression Analysis - Data Analysis Fundamentals Guide). See
Appendix B for representative Signals and Change p-values for selected Probe Sets from
this work. The results of these comparisons were exported into Excel and visualized by
subsequent importation into Spotfire Decision Site 8.1 software (Spotfire, Inc.,
Somerville, MA).
Gene Ontology Analysis
For acquiring, analyzing and organizing the genetic information resulting from
the microarray experiments, selected probe set names were entered into the Gene
Ontology Mining Tool within NetAffx™ Analysis Center
(http://www.afifymetrix.com/products/software/specific/netaffit.affx).

RT-PCR

For measuring changes in transcript levels, Taqman® or SYBR Green two-step
RT-PCR assay (ABI) was used. Briefly, the reverse transcriptase (RT) step was
conducted by mixing 1-2 fig total RNA with IX TaqMan RT buffer, 5.5 mM MgCk,
500 pM dNTPs, 2.5 pM random hexamers, 0.4 U/pl RNase inhibitor, ±1.25 U/pl reverse
transcriptase [Taqman® RT reagents (ABI # N808-0234)]. Thermal cycling parameters
for RT reactions included a primer incubation step at 25 °C for 10 min, RT at 48 °C for
30 min and an RT inactivation step at 95 °C for 5 min. In the subsequent PCR reactions,
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we combined Taqman® Universal PCR Master Mix (ABI # 4304437) or SYBR Green
PCR Master Mix (ABI #4309155), oligonucleotide primers, and oligonucleotide probes,
see Table 4, with 1:10-1:200 dilution of RT reaction for unknowns or 1:50-1:50,000
dilution of murine genomic DNA (100 ng/pl stock, a gift from William Blake, Pharmacia
Corp. Kalamazoo, MI) or human genomic DNA (Taqman Control Genomic DNA
(human), # 4312660, ABI) for standards. These 25 pi PCR reactions were placed in an
ABI Prism 7700 Sequence Detection System (ABI). Thermal cycling parameters
included an incubation step at 50 °C for 2 min, Amplitaq Gold (component of Universal
PCR Master Mix) activation step at 95 °C for 10 min, and 40 cycles of PCR consisting
of a denaturation step at 95 °C for 15 sec and an annealing/extension step at 60 °C for
1 minute. Using the ABI Prism quantitation software, relative transcript amounts were
determined. We used glyceraldehyde phosphate dehydrogenase (GAPDH) transcript
levels to normalize COX Vla-H and other transcript levels, as we found GAPDH to be
constitutively expressed throughout the treatments. Fold increases were calculated as a
ratio o f transcript levels in treated versus untreated control samples. After a few RTPCR experiments, we replaced genomic DNAs with pooled RT reactions in PCR
reactions used for standard curve determinations. This replacement was necessary as we
were unable to synthesize detectable PCR products using COX Vla-H primers with the
mouse genomic DNA, (see Results section).
Data Analysis

We used Unistat (London, England, www.unistat.com) to perform t-test
statistical determinations. For the time-course and concentration-response experiments,
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data were analyzed in GraphPad Prism Software version 4.03 (GraphPad Software
Incorporated, San Diego, CA).

Table 4. RT-PCR Oligonucleotide Primers
Gene
Name

Organism

Primer Name

Accession
Number

Sequence 5'->3'

(catalog
number)
COX Vla-H

GAPDH

COX VI

COX Vb

Mouse

Rat

Mouse

Mouse

mCOX VlaH For

NM_009943

accacgagcgcccagag

COX VlaH Rev

NM_009943

aggcgaagggcttggttc

COX VlaH Probe
(FAM)

NM_009943

FAMcatcccgtatcaccacctccgcatTAMRA

rodent GAPDH Forward

(ABI #4308313)

proprietary

rodent GAPDH Reverse

(ABI #4308313)

proprietary

rodent GAPDH Probe
(VIC)

(ABI #4308313)

proprietary

mCOX IV For

M37831

catgaaggccaaccccatt

COX IV Rev

M37831

gcagcgggtctcacttct

COX IV Probe (FAM)

M37831

FAMactcattcttgtcatagtcccacttggTAMRA

mCOX Vb For

X52157

cagcttcaggcaccaagga

COX Vb Rev

X52157

cacagatgcagcccactattctc

COX Vb Probe (FAM)

X52157

FAMccctaatctagtcccgtccatcagcaa
-TAMRA
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RESULTS
Previous work has shown that chloramphenicol affects proliferation of a variety
o f cells (Morley, Furness, & Higgs, 1974; Ruben & Hooper, 1978; Madeira-Lopes &
Van Uden, 1981; Leiter et al., 1999; Kang et al., 2005). In order to examine the effects
of chloramphenicol on erythroid precursor proliferation to global transcription, we
needed to set up an erythroid cell model that was sensitive to chloramphenicol. We chose
BB 88 murine erythroleukemia cells, a hematopoietic model described earlier in the
Introduction section. These cells can be cultured easily and Figure 6 shows a
representative growth curve for these cells. For the first 4 days in culture, BB 88 cells
diluted back to 20K per milliliter (20K/ml) grew exponentially and a doubling time of 12
hours was estimated. Thereafter, cells grew more slowly. In this experiment where the
culture medium has not been replenished, by 7 days, BB 88 cell growth was arrested.
After determining these basic BB 88 growth characterictics, we determined the effects of
chloramphenicol on cell proliferation. BB 88 cell cultures were set up as in Figure 6 and
after 24 hours, various amounts (0-200 p.M) of chloramphenicol were added. After an
additional 48 hours, cell counts of the various cultures were determined (Figure 7). The
cell counts from this experiment fitted nicely a sigmoidal dose response curve such that
the concentration at which chloramphencicol inhibited BB 88 proliferation by 50%
was 43 pM.
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Figure 6 . Proliferation of BB 88 Murine Erythroleukemia Cells.
BB 88 cells were maintained at 37°C under 5% CC^in motionless suspension culture in
RPMI 1640 supplemented with 10% FBS (heat-inactivated), lOpM P-mercaptoethanol,
L-glutamine, and Penicillin-Streptomycin (100 Units/ml and 100 pg/ml, respectively).
Cells were seeded at 2 x 104/ml in 24-well Costar culture dishes, ~ 1 ml/well. Cell counts
were determined using a Coulter Counter ZM (Beckman-Coulter Inc.) every 24 hours
over 7 days (168 hours). Each square represents the mean of triplicate determinations.
Using GraphPad Prism, the data was fitted using the Gompertz equation: Y=N0+C*exp(exp((2.718*mue/C)*(Lag-X)+l)). For fitting bacterial growth data (sigmoidal); NO = log
initial number of cells; C = difference between initial and final cell numbers; Lag = delay
before growth, same units as X; mue = maximum specific growth rate.; X = time, Y =
log cell number. Inset graph shows logarithmic growth of BB 88 cells over first 4 days.
Using linear regression, doubling time of BB 88 cells is 12 hours.

In the next experiment, we chose to follow BB 88 proliferation after the addition
o f 50 pM chloramphenicol. As can be seen in Figure 8, chloramphenicol affects BB 88
cell growth rate. After 5 days of antibiotic exposure, cell number in cultures containing
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Figure 7. Effect of Chloramphenicol on Proliferation of BB 88 Cells.
Cells were cultured as described in Figure 2. After 24 hours different amounts of
chloramphenicol (0-200 pM) were added to cells that were about 325K/ml wells. After
an additional 48 hours, cells were harvested and counted. Cultures without
chloramphenicol reached 1290K cells/ml. Each square represents the mean of triplicate
proliferation determinations. Concentration response was generated using a Sigmoidal
dose response equation within GraphPad Prism.

chloramphenicol are reduced by more than one half, declining from about 2660K cells/ml
to about 1020K cells/ml, in 0.1% EtOH and 50 pM chloramphenicol, respectively. In
this experiment, a decline in cell number can be seen shortly after antibiotic addition. As
depicted in the inset to Figure 8, after 24 hours in culture, proliferation decreased
significantly (P<0.021) from 226K cells/ml in 0.1% EtOH to 182K cells/ml in 50 pM
chloramphenicol. Despite there being a decline in the number of cells/ml after 6 hours in
chloramphenicol, this decline was not significantly different from ethanol treated control
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Figure 8 . Effect of Chloramphenicol Treatment on BB 88 Cell Proliferation Over Time.
BB 88 cells cultures were set up and monitored as before, except after 24 hours, cultures
received 50 pM chloramphenicol or ethanol (EtOH) (0.1% final concentration) and
proliferation was monitored for an additional 5 days (144 hours). Each point represents
the mean of triplicate determinations. Inset is an enlargement of the first 60 hours.
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cultures (P< 0.1). Using linear regression, we examined the effect of the antibiotic
treatment on proliferation over the first 48 hours. We calculated growth rates of 11.75
hours and 13 hours per doubling in the cultures containing 0.1% EtOH and 50 p.M
chloramphenicol, respectively. We examined cell viability using trypan exclusion and saw
no difference in the uptake of this stain in chloramphenicol and untreated cells (data not
shown).
These effects of chloramphenicol on BB 88 cell proliferation were useful in
setting up an experiment to monitor global transcription changes, the primary focus of
this work. We treated proliferating BB 88 cells with and without 50 pM chloramphenicol.
After 0 and 24 hours treatment, we counted and harvested cells. While cell numbers for
these cultures were not monitored beyond the last harvest time, as seen before, there is a
significant decrease (P<0.005) in cell number in the 24 hour antibiotic-treated cultures
compared to the control cultures (0.1% EtOH), Figure 9A. In order to perform
microarray hybridization experiments, we needed to prepare RNA from these treated
cells. Although we used less Trizol per cell number than was suggested by the
manufacturer, there was no significant difference in the RNA amounts in treated and
control cells, Figure 9B.
To remove any contaminating DNA, we treated RNA that was immobilized on
Qiagen RNeasy columns with DNAse. To check for residual contaminating DNA, we
analyzed DNAse-treated RNAs using an Agilent Bioanalyzer (Agilent Technologies,
Palo Alto, CA). Although we could not assess the mRNA component of each sample, we
determined that the RNA samples were undegraded and intact based upon the
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Figure 9. Effect of Chloramphenicol on Growth and RNA in BB 88 Cells.
BB 88 cells were diluted back to 20K/ml in 800 ml media and dispensed (100 ml) into 8 x
175 cm2 culture flasks (Corning # 431080). After 24 hours, four cultures were treated
with 50 pM chloramphenicol (treated) and four cultures were treated with ethanol (0.1%
final) (control). Immediately, one control and one treated culture were counted and
harvested for RNA. After an additional 24 hours, the remaining cultures were counted
and cells harvested for RNA. A. Cell counts in the various cultures during the
experimental treatment, 8 cultures at 0 hours, 2 cultures at 24 hours (one control, one
treated), and 6 cultures at 48 hours (3 control and 3 treated). B. RNA amounts (pg/cell)
in cells harvested at 24 hours (2 x control 0 hours) or 48 hours (3 x control 24 hours and
3 x treated 24 hours). Bars represent the mean of either duplicate or triplicate
determinations. There is no significant difference between the yields of RNA from the
treated-24 hours versus the control-0 and 24 hours cells.

visualization of the 28S and 18S ribosomal RNA bands running at about 4000 base pairs
(bp), respectively, see Figure 5. Since the RNA standards appeared very light in this
particular electropherogram, they were marked by bars. At this point, we used these
RNAs to synthesize cDNA and biotinylated cRNAs, see Methods. We prepared and
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analyzed cDNA from equal RNA aliquots. These cDNAs were used to make biotinylated
cRNA using a commercial in vitro transcription kit, see Methods. Figure 10 shows the
results obtained from the in vitro transcription reactions done on the control and on
treated RNA groups. The yields, ranging from 56.2 pg to 110.8 pg (average yield of
75.6 pg), were within the manufacturer’s specifications (data not shown). There was no
significant difference (P<0.8) between any of average yields of these three groups of
RNAs.

100 - !

control 0 h ou rs

control 2 4 h ou rs

tr ea te d 2 4 hou rs

Treatments

Figure 10. In Vitro Transcription Results - Yield of cRNA.
Double-stranded cDNA was synthesized from 7.5 pg total RNA aliquots. cDNAs were
in vitro transcribed and then reaction products were passed over Qiagen RNeasy
columns. Eluted RNA was quantified spectrophotometrically, see Methods. Bars
represent the mean of either duplicate (Control 0 hours) or triplicate (control 24hours
and treated 24 hours) determinations. There is no significant difference between the
average yields of these RNA (P<0.8).
To obtain optimized cRNA for hybridization Targets, we fragmented cRNA by
heating. RNA samples were compared on agarose gels, Figure 11. First, we compared
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Figure 11. Gel Analysis of Fragmented cRNA Targets.
Fifteen micrograms cRNA aliquots were fragmented in thirty microliters buffer, see
Methods. Five microgram aliquots were electrophoresed on a 1% Agarose gel, stained
with Sybr Green (Molecular Probes), and photographed under UV light (Sambrook et
al., 2001). Lanes: 1, Roche VIDNA molecular weight markers; 2, total RNA control 0
hours; 3, cRNA control 0 hours; 4, cRNA treated 24 hours; 5-6, fragmented cRNA
control 0 hours; 7-9, fragmented cRNAs control 24 hours; 10-12, fragmented cRNAs
treated 24 hours; 13, 2.5 pg tRNA control.
total RNA with the unfragmented cRNA. Unfragmented cRNAs ran as smears between
about 200 base pairs and on up above the highest DNA marker at 2176 base pairs. Also,
these samples had no ribosomal bands, unlike the total RNA sample; compare lanes 3
and 4 with lane 2. All fragmented cRNAs from this experiment, lanes 5-12, migrated
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with tRNA, lane 13, or near the lowest DNA marker at 154 base pairs (bp), lane 1.
Because these particular cRNAs were of a particular fragment size as described in the
Affymetrix technical manual (35-200 bp), we proceeded to hybridize these cRNA
Targets to Affymetrix U74Av2 microarrays.
As part of our microarray technology evaluation, we had hybridized several
cRNA Targets to Affymetrix Test 2 arrays to assess our cRNA Targets and the
hybridization reaction and reagents (data not shown). These arrays contain far fewer
Probes Sets than the U74Av2 microarrays that we used here; however, they contain
Probe Sets from commonly expressed genes from the human, mouse, rat, and yeast
genomes. For each of these genes, Probe Sets derived from the 5', middle, and 3' ends of
the gene are represented on the microarray. Also, theses arrays contained Probe Sets for
genes that should be under-represented, such as murine 18S RNA (Affymetrix Probe Set
name, 18SRNAMUR). Finally, these arrays also contain Probe Sets for control
transcripts (BIOB, BIOC, BIODN, and CREX), such that the Signal intensity is
generally proportional to the amount of the respective cRNA Target spiked into the
hybridization mix (see Methods). By obtaining Signal measurements from these various
Probe Sets, we can identify cRNA Targets that may be degraded or of poor hybridization
quality.
Since the murine U74Av2 arrays contain most of these control Probe Sets, we
decided to hybrize our fragmented cRNA Targets to the U74Av2 microarrays directly.
After hybridizing, washing, and scanning the eight U74Av2 Arrays, we entered and
analysed the various scanned output files within Affymetrix Microarray Suite version 5.0
software. After surveilling the hybridization signals to the various control Probe Sets
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described above, we proceeded to perform some basic analyses. The first thing we
wanted to know is whether there were differences between the transcription profiles on
the control microarrays (RNA samples from two 0 hour [untreated] and three 24 hours
[0.1% EtOH] cultures). While we did not expect to find many differences between
transcription profiles from these control RNA samples, we felt that in order to alleviate
large numbers of misinterpretations of the relative Signal intensities of the
chloramphenicol-treated RNA samples, an analysis of control raw data needs to be
evaluated. We started by performing six pairwise comparisons on the raw data
(Affymetrix Signals) of three 24 hours control cultures (0.1% EtOH treated) verses the
two 0 hour control cultures (untreated). Next, we did three pairwise comparisons of
each 24 hours control cultures (Signal intensities from one 24 hours control microarray
were compared to the Signal intensities of the other two replicate 24 hours control
microarrays). The output from all these comparisons was exported into Excel, sorted,
combined, and then imported into Spotfire 4.3. Within Spotfire, we were able to
visualize and delineate those transcripts that had changed, as defined by the Affymetrix
Change Call, see Transcript Analysis Algorithm section in Methods and the Affymetrix
Gene Expression Analysis - Data Analysis Fundamentals.
Using GraphPad Prism, Figure 12 gives a visualization of the results of these
control group comparisons. Unexpectedly, there was a larger number of transcripts
changed within the 24 hour control group comparisons (average = 880 for the three
comparisons), versus the 24 hour versus 0 hour control group comparisons (average =
635 for the six comparisons). However, overall number of changes between these two
groups o f pairwise comparisons (880 versus 635) is not significantly different (p<0.19)
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Figure 12. Number of Changed Transcripts in RNA Samples from Control BB 88
Cultures.
Comparisons were performed using the Affymetrix hybridization output results from
three 24 hour control (RNA from BB 88 cultures grown in 0.1% EtOH for 24 hours) and
the two 0 hour control samples (RNA from BB 88 cultures grown in 0.1% EtOH for 0
hours). Six pairwise comparisons were done between the three 24 hours control and the
two 0 hour control results (24 hrs versus (vs) 0 hrs) and three pairwise comparisons
were done between the three 24 hour control results (24 hrs vs 24 hrs). A. Average total
number of transcripts changed as a result of the comparisons (t-test, P<0.19). B. Same
data as in A, re-plotted to show the average number of transcripts increased (Inc),
decreased (Dec), marginally increased (MI), and marginally decreased (MD), as a result
of the comparisons. Each bar representing the 24 hrs vs 0 hrs comparisons is theaverage o f six determinations, while each bar representing the 24 hrs vs 24 hrs
comparisons is the average of three determinations.
(Figure 12A). In Figure 12B, the same data are plotted differently to visualize better the
kinds of changes that have occurred. Here again, when looking at the average number of
transcripts that have changed per comparison, while there are more increased (Inc),
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decreased (Dec), marginally increased (MI), or marginally decreased (MD) transcripts in
the within 24 hour control group, these changes were not significant. Also these graphs
show that in all of these comparisons, the number of transcripts that were marginally
increased (MI) or marginally decreased (MD), versus the control transcript levels, was
less than 10% of the total number of changed transcripts. Taking the union of all the
transcripts that changed in each of these pairwise comparisons and then sorting these
transcripts within Spotfire, we were able to visualize what particular changes were
common to all the comparisons within a group (data not shown, see Figure I4C for
representative plot). In examining the three 24 hour control pairwise comparisons, we
determined that there were a total of 2641 transcripts (represented by a unique probe
set) that were changed out o f a total of 37464 paired transcripts (12488 transcripts per
microarray times three pairwise comparisons). From these changes, only 95 transcripts
out of a total of 12488 transcripts (Probe Sets) on each U74Av2 microrarray were
changed in all three 24 hour pairwise comparisons. Since these three comparisons were
between replicates from within the control group, transcripts that were either increased
or decreased in two of the three pairwise comparisons were decreased or increased in the
third comparison, respectively. Also, it should be noted that sometimes the micorarray
contains multiple transcripts (Probe Sets) that are associated with the same gene. It turns
out that three of the 95 changed transcripts were associated with the transferrin receptor
and this transcript increased on two of three comparisons. Thus, there were annotations
for 93 separate transcripts in BB 88 cells that fluctuate randomly as a result of being
cultured in 0.1% EtOH for 24 hours in different flasks. Further, about half of these
transcripts changed less than two-fold.

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

65
In examining more closely the other six pairwise comparisons (three 24 hour
0.1% EtOH treated cultures versus the two 0 hour untreated control cultures), out of a
total of 74928 paired transcripts (12488 transcripts per microarray times six pairwise
comparisons), there were a total of 3809 changed. Of these transcripts, there were only
48 transcipt comparisons that were commonly changed in all six pairwise comparisons.
These changes represented only 8 transcripts (48 transcipt changes/6 comparisons).
Overall these eight transcripts were increased as a result of being cultured in 0.1% EtOH
for 24 hours and only two transcripts were increased more that two-fold (data not
shown).
To identify the transcripts that were changed in BB 88 cells treated with
chloramphenicol, we analysed the output from three U74Av2 micoarrays hybridized to
RNA from 50 p.M chloramphencicol-treated cultures. Similar to the pairwise
comparisons described above, we performed two sets of comparisons (Figure 13). First,
we compared transcript changes on the microarrays hybridized to RNAs from cells
treated only with chloramphenicol. Out of a total of 37484 comparisons an average of
163 transcript changes per comparison (Figure 13A). From this total number of changes,
86 transcripts had changed (increased or decreased) more than two-fold. Further, only 9

transcripts were commonly changed in all three comparisons. These 9 transcripts,
representing three unique genes, were all changed less than two-fold (data not shown).
When the nine pairwise comparisons between the Affymetrix hybridization results from
the three chloramphenicol-treated micorarrays (Treated) and the three Control
micorarrays were tabulated, there was an average of 1310 transcript changes per
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Figure 13. Number o f Changed Transcripts in RNA Samples from Treated and Control
BB 88 Cultures.
Comparisons were performed using the Affymetrix hybridization output results from the
three Treated (RNA from BB 88 cultures grown for 24 in 50 p.M chloramphenicol) and
the three Control samples (RNA from BB 88 cultures grown in 0.1% EtOH for 24
hours). Nine pairwise comparisons were done between the three Treated and the three
Control samples (Treated vs Control) and three pairwise comparisons were done
between the three Treated samples (Treated vs Treated). A. Average total number of
transcripts changed as a result of the comparisons (equal variance t-test, P<0.0001). B.
Same data as in A, re-plotted to show the average number of transcripts increased (Inc),
decreased (Dec), marginally increased (MI), and marginally decreased (MD), as a result
of the comparisons. Each colored bar representing the Treated vs Control 24 hrs
comparisons is the average of nine determinations, while each bar representing the
Treated vs Treated 24 hrs comparisons is the average of three determinations (equal
variance t-test, P<0.0001).
comparison (Figure 13). This number of transcripts was significantly larger (t-test,
P<0.0001) than the average computed for the within treatment comparisons (Figure
13A). When examining the kinds of changes that were made as a result of the
chloramphenicol, there were significantly more (P<0.025 for all comparisons) increased
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(Inc), decreased (Dec), marginally increased (MI), and marginally decreased (MD)
transcripts in comparisons of chloramphenicol-treated BB88 cells to control cells versus
the comparisons o f treated cells to themselves (Figure 13B).
Microsoft Excel files containing the increased or decreased transcript data from
the pairwise comparisons described above were imported into Spotfire (Figure 14).
Spotfire allows the visualization of complex datasets and we used this software to
identify common increased or decreased transcripts from replicate samples. The bar
graph in Figure 14A enumerates the number of changes in each pairwise comparison. By
taking the union o f these transcripts (11789) and plotting their fold change (Signal Log
Ratio) versus their Affymetrix transcript identifier (Probe Set Name), a complex pattern
appears (Figure 14B). While it appears that there may be two groups of transcripts
whose transcript levels have increased greatly, we used Spotfire to eliminate transcripts
whose expression did not change in all 9 pairwise comparisons. Each vertical line
reaching the top of the graph in Figure 14C delineates a transcript that was increased in 9
of 9 Affymetrix comparisons. The fold changes for these remaining transcripts (1791
common to all nine pairwise comparisons) are shown in Figure 14D. From this
visualization, one can easily identify three sets of transcripts that have changed
dramatically, two that have increased, and one that has decreased. This set of changed
transcripts, represents 199 genes, 106 genes whose transcripts have decreased and 93
genes whose transcripts have increased.
In Table 5 and Appendix B, we have reported not only the fold changes for those
transcripts that have decreased (Log2 ratio less than or equal to -1 ) or increased (Log2
ratio greater than or equal to 1) two-fold or greater, but also have summarized gene
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Figure 14. Transcripts Increased and Decreased as a Result of Chloramphenicol
Treatment.
Microarrays hybridized to RNAs from three treated (50 pM chloramphenicol) and three
control (0.1% EtOH) BB88 cultures were analysed and compared within Microarray
Suite 5.0. Comparison results were combined in Excel and visualized in Spotfire to
obtain common transcripts changed, see Method. A. Number of transcripts changed in
each pairwise comparison. B. Union of changed transcripts, fold change (Signal Log
Ratio) versus Probe Set Name. C. Visualization of the common transcripts changed
(199) in all nine pairwise comparisons. D. Visualization of fold change of the 199
transcripts.
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ontology findings for these transcripts. Of the seven transcripts that decreased, two,
Gpd2 and Pgaml, are involved in fatty acid and glucose metabolism, respectively and
two o f the transcripts code for integral membrane transporters (Table 5A). Slc2al is a
glucose transporter, while Aqpl is involved in water transport. Ptger4 is an integral
membrane receptor that binds prostaglandins, while Bhlhb2 encodes a nuclear
transcription factor. The seventh transcript, A030007L17Rik, remains unannotated. Of
the 49 transcripts that increased more than two-fold after chloramphenicol treatment,
two Probe Sets, 100306_at and 92268_at, code for the same unannotated transcript,
2700007P21Ri (Table 5B). There were additional redundancies with several other Probe
Sets. Probe Sets, 103922_f_at and 103921_i_at, code for Cyb5rl, a nuclear-encoded
mitochondrial protein involved in electron transport, Probe Sets, 100592_at and
160530_at, encode a growth hormone inducible integral membrane protein, and Probe
Sets, 102879_s_at and 101793_at, encode an immunoglubulin receptor. These
redundancies not only bring some confirmation to the identification of transcripts that
have been affected by chloramphenicol, but also reduce the number of unique transcripts
that have increased in BB88 cells treated with chloramphenicol to forty-five. Ten of the
forty-nine total increased transcripts (20.4%) either encoded transcription factors or
were involved in gene expression or cell cycle control (marked yellow in Table 5B).
Seven transcripts (14.3%) were associated with amino acid or protein metabolism
(marked red in Table 5B). As of this writing Affymetrix NetAffx Center annotated one
Probe Set from this group, 161221_f_at, as asparagine synthetase (Table 5B). From our
results and the Affymetrix nomenclature, this Probe Set’s identity is suspicious.
Affymetrix has another Probe Set, 95133_at, identified as asparagine synthetase and
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Table 5. Decreased and Increased (> 2-fold) Transcripts in Chloramphenicol-Treated BB88 Cells
(Transcripts have been color coded by biological process and molecular function based upon Affymetrix NetAffx gene
ontology (GO) analysis.)
A. Decreased Trancripts
# De
creased

Probe Set
Name

Gene Symbol

average
signal
log2 ratio

Change pvalue

Gene Title
facilitated glucose
transporter
phosphoglycerate
mutase 1

GO Biological
Process
Description

GO Molecular
Function
Description

GO Cellular
Component
Description

Pathway

integral to
glucose transporter
membrane
activity
bisphosphoglycerate
Glycolysis_and_
phosphatase activity
cytosol
Gluconeogenesis
glycolysis
glycerol-3phosphate
glycerol-3Fatty_Acid_
dehydrogenase
mitochondrial
glycerol phosphate
phosphate
inner membrane
dehydrogenase 2
activity
Degradation
metabolism
water transporter
integral to
water
...
membrane
aquaporin 1
transport/excretion
activity
Prostaglandin_
G-protein coupled
synthesis_
integral to
prostaglandin E
receptor protein G-protein coupled
regulation
membrane
receptor 4
signaling pathway receptor activity

1

93738 at

Slc2al

-2.4

1.00E+00

glucose transport

2

160091 at

Pgaml

-1.3

1.00E+00

3

98984 f at

Gpd2

-1.1

1.00E+00

4

93330 at

Aqpl

-1.5

1.00E+00

5

103362 at

Ptger4

-1.2

1.00E+00

6

104701 at

Bhlhb2

-1.0

1.00E+00

basic helix-loophelix domain

regulation of
transcription

7

94995 at

A030007L17Rik

-1.0

1.00E+00

RKEN cDNA

—

transcription
regulator activity
—

nucleus
—

—
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Table 5 —Continued
B. Increased Transcripts

#

Probe Set
Name

Gene
Symbol

average
signal
log2 ratio

Change
p- value

1

161067_at

Trib3

2.7

1.00E-06

2

101429_at

Ddit3

2.4

0.00E+00

tribbles homolog 3
(Drosophila)
DNA-damage
inducible
transcript 3

Gene Title

GO Biological
Process
Description

3

103006_at

Atf5

2.1

2.10E-05

activating
transcription
factor 5

4

102292_at

Gadd45a

2.1

1.00E-06

GADD 45 alpha

5

92925_at

Cebpb

1.5

0.00E+00

C/EBP beta

6

98122_at

Lmo4

1.5

7.40E-05

LIM domain only
4

regulation of
MAPK activity
regulation of
transcription,
DNA-dependent
regulation of
progression
through cell cycle
-regulation of
transcription,
DNA-dependent
regulation of
cyclin-dependent
protein kinase
activity
positive
regulation of
transcription
transcription
from RNA
polymerase II
promoter

activating
transcription
factor 4

gluconeogenesis positive
regulation of
transcription from
RNA polymerase
II promoter

7

100599_at

Atf4

1.2

1.00E-06

GO Molecular
Function
Description
transcription
corepressor
activity - kinase
activity
transcription
corepressor
activity

sequencespecific DNA
binding

GO Cellular
Component
Description

nucleus

nucleus

transcription
factor complex

nucleus

protein binding
sequencespecific DNA
binding

nucleus cytoplasm

transcription
factor binding

transcription
factor complex

transcriptional
activator activity

Pathway

nucleus

Smooth
muscle
contraction

Cell Cycle
Ovarian
Infertility
Genes

Smooth
muscle
contraction
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Table 5 —Continued
Probe Set
Name

94135 at

160535 at

10

95502 at

11

104144 at

Gene
Symbol

Tcfcp2

Nfe211

average
signal
log2 ratio

1.2

1. 1

Change
p-value

Gene Title

GO Biological
Process
Description

4.70E-05

transcription
factor CP2

0.00E+00

erythroid derived
nuclear factor 2

regulation of
transcription from
RNA polymerase
II promoter
transcription
from RNA
polymerase II
promoter - heme
biosynthesis
negative
regulation of
transcription

Sirt2

1.0

1.00E-06

sirtuin 2

Gtpbp2

1.7

2.00E-06

GTP binding
protein 2

12

92589 at

Psph

1.3

0.00E+00

phosphoserine
phosphatase

13

97960 at

Usp22

1.2

0.00E+00

ubiquitin specific
peptidase 22

14

161221 f at

Asns

1.2

1.33E-04

asparagine
synthetase

15

98042 at

Scpepl

1.1

1.43E-04

serine
carboxypeptidase 1

GO Molecular
Function
Description

GO Cellular
Component
Description

transcriptional
activator activity

transcription
factor complex

transcription
factor activity

extracellular
space III
nucleus

deacetylase
activity

chromatin
silencing
complex

Pathway

Glycine,
serine and
threonine
metabolism

soluble
fraction

Nitrogen
metabolism

■~o
to
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Table 5 —Continued

16

17

18

19

20

GO Biological
Process
Description

GO Molecular
Function
Description

Gene
Symbol

average
signal
log2 ratio

Change
p-value

Gene Title

160328 at

Lonpl

1.0

3.00E-06

Ion peptidase 1

mitochondrion

1.00E-06

keratinocyte
associated protein
2

integral to
membrane

97268 i at

101441 i at

96160 at

100943 at

Krtcap2

Itpr2

Slc6a9

Slcla4

1.0

1.4

1.3

1.1

1.30E-05

inositol 1,4,5triphosphate
receptor

calcium ion
transport

inositol 1,4,5triphosphatesensitive
calcium-release
channel activity

4.67E-04

solute carrier
family 6

amino acid
transport

sodium:amino
add symporter
activity

integral to
membrane

2.90E-04

solute carrier
family 1

neutral amino
acid transport

neutral amino
acid transporter
activity

integral to
membrane

integral to
membrane
integral to
membrane

21

103818 at

Slc7a7

1.1

5.90E-05

solute carrier
family 7

amino acid
transport

amino acidpolyamine
transporter
activity

22

104328 at

Aqp9

1.0

3.40E-05

aquaporin 9

water transport

water channel
activity

23

GO Cellular
Component
Description

Probe Set
Name

101793 at

Fcgrl

5.2

3.10E-05

high affinity Fc
receptor, IgG

integral to
membrane

integral to
membrane

Pathway

Smooth
muscle
contraction

Inflamma
tory
Response
Pathway
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Table 5 —Continued

#

24

25

Probe Set
Name

Gene
Symbol

101845_s_at

Csprs III
Spl00-rs

101209_at

Fcerla

average
signal
log2
ratio

4.1

3.0

GO Biological
Process
Description

GO Molecular
Function
Description

GO Cellular
Component
Description

Change
p-value

Gene Title

2.38E-03

component of
SplOO-rs

nucleus integral to
membrane

3.11E-04

high affinity Fc
receptor, IgE

integral to
plasma
membrane

26

102879_s_at

Fcgrl

2.4

0.00E+00

high affinity Fc
receptor, IgG

integral to
membrane

27

102337_s_at

Fcgr2b

1.1

2.30E-05

low affinity Fc
receptor, IgG

integral to
membrane

28

99330_at

Csf2ra

1.0

1.88E-03

29

99667_at

Cox6a2

4.8

0.00E+00

CSF2 receptor
cytochrome c
oxidase, subunit
Vla-H

30

103922_f_at

Cyb5rl

2.0

F00E-06

cytochrome b5
reductase 1

0.00E+00

phosphoenol pyruv
ate carboxykinase
2

31

97398_at

Pck2

1.9

Pathway

Inflamma
tory
Response
Pathway

integral to
membrane
mitochon
drion

Electron
Transport
Chain

mitochon
drion

Pyruvate
metabolism
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Table 5 —Continued

#

Probe Set
Name

Gene
Symbol

average
signal
log2
ratio

32

103921_i_at

Cyb5rl

1.5

3.10E-05

cytochrome b5
reductase 1

33

97870_s_at

Eroll

1.0

5.00E-06

EROl-like (S.
cerevisiae)

endoplasmic
reticulum

34

160108_at

Nuprl

1.5

1.77E-04

nuclear protein 1

nucleus

35

103520_at

Vegfa

1.2

1.54E-04

VEGFA

extracellular
matrix

36

95637_at

Flnb

1.2

1.00E-06

37

160463_at

Mydll6

1.0

1.30E-03

38

94359_at

Plekhal

1.9

4.00E-06

beta filamin
myeloid
differentiation
primary response
gene 116
pleckstrin
homology domain
containing

39

100306_at

2700007
P21Rik

1.3

6.30E-05

40

100592_at

Ghitm

1.3

0.00E+00

Change
p-value

Gene Title

RIKEN cDNA
2700007P21 gene
growth hormone
inducible
transmembrane
protein

GO Biological
Process
Description

GO Molecular
Function
Description

GO Cellular
Component
Description

cytoplasm cytoskeleton

membrane

integral to
membrane

Pathway
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Probe Set
Name

41

100920 at

42

92268 at

43

160530 at

average
Signal
Log2
ratio

Change
p-value

1.3

1.00E+00

2700007
P21Rik

1.2

1.00E-06

Ghitm

1.1

3.70E-05

Gene
Symbol

Gene Title

GO Biological
Process
Description

RIKEN cDNA
2700007P21 gene
growth hormone
inducible
transmembrane
protein

44

102249 at

Avil

2.6

1.00E-06

advillin

45

94278 at

Lcpl

1.4

3.00E-06

lymphocyte
cytosolic protein 1

actin filament
organization/
barbed-end actin
filament capping
response to
wounding I I I actin
filament bundle
formation

46

96199 at

Mtml

1.7

1.00E-06

47

102313 at

Gchl

1.6

1.00E-06

GTP
cyclohydrolase 1

nitric oxide
biosynthesis

3.00E-06

glycophorin A

regulation of
response to
osmotic stress

1.20E-05

phosphodiesterase
6D, cGMPspecific, rod, delta

response to
stimulus

49

102770 at

160602 at

Gypa

Pde6d

1.6

1.2

GO Cellular
Component
Description

Pathway

integral to
membrane

X-linked
myotubular
myopathy gene 1

48

GO Molecular
Function
Description

phospholipid
dephosphoryla
tion

actin binding calcium ion
binding - protein
binding

actin
cytoskeleton

actin filament
binding

cytosol - actin
filament

inositol
phosphatase
activity vesicular
trafficking?
GTP
cyclohydrolase I
activity
protein binding protein
homodimer ization activity
3',5'-cyclicnucleotide
phosphodiesterase activity

cytopalsm membranes
cytoplasm

Folate
biosynthesis

integral to
membrane

--j

CT\
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we have shown that its transcripts were increased slightly by 24 hours ethanol treatment.
However, transcripts for Probe Set 95133_at were unaffected by chloramphenicol
treatment. This inconsistency suggests that gene identification and annotation are
ongoing processes. In time, perhaps this discrepancy and the true identity of Probe Set
161221_f_at will be known. Five transcripts were transporters (10.2%), with three of the
five transporters being involved in amino acid transport (marked green in Table 5B). Six
increased transcripts (12.2%) appear to be receptors, with half of these receptors having
immunoglobulins as their ligand (marked blue in Table 5B). Five transcripts (10.2%)
were involved in either electron energetics or glucose metabolism (marked orange in
Table 5B). There were four transcripts (8.2%) having something to do with cell
proliferation, growth, development, and/or the cell cycle (marked light gray in Table 5B).
Six transcripts (12.2%) were not readily grouped with any biological process or
molecular function, although two of theses transcripts appear to code for membraneous
proteins (marked dark gray in Table 5B). Two increased transcripts (4.1%), Avil and
Lcpl, coded for actin binding proteins (unmarked in Table 5B), while the four remaining
transcripts (8.2%), M tml, Gchl, Gypa, and Pde6d, are more unique in their ontology,
coding for a phosphatase, hydrolase, integral external membrane protein, and a
nucleotide phosphodiesterase, respectively (marked tan in Table 5B).
The transcript that decreased most in this experiment was identified by Probe Set
93738-at (Table 5A and Appendix B). This Probe Set matched the gene for the
facilitated glucose transporter. Similarly, two transcripts with some of the larger fold
increases, 5.2 and 3.0 log2 ratios, were Probe Sets, 101793_at and 101209_at,
respectively (Table 5B and Appendix B). From the NetAffx Analysis Center, these
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transcripts code for Fc receptor of imunoglobulins IgG and IgE, respectively. In
chloramphenicol-treated BB88 cells, we saw large increases (4.8 signal log2 ratio) in the
transcript for Affymetrix Probe Set 99667_at (Table 5A and Appendix B). We decided
to study further this phenomenon not only because of these dramatic increases in
99667_at mRNA, but also because Probe Set 99667_at codes for COX Vla-H, a subunit
of mitochondrial cytochrome c oxidase, (Bread 1969; Wilkie, 1977) (Figure 15). Using
RT-PCR, we decided to confirm the finding that chloramphenicol increases COX Vla-H
RNA in RNA samples from chloramphenicol-treated BB88 cells. First, COX Vla-H
oligonucleotide primers and probes were designed, see Methods and Table 4. These

/

/

Xnaex

roitoduMsldaJ
m tr s ib tm t
t-te.tnx

CyfcxhzoBie e oxMase (fem ne)

Figure 15. Model of Bovine Cytochrome C Oxidase.
Schematic diagram of cytochrome c oxidase (COX) based upon crystal structure of
bovine COX (Tsukihara et al., 1996). This diagram shows the COX Vla-H subunit
spanning the mitochondrial membrane and interacting with the COX I and COX III
subunits. The diagram was downloaded from the Kyoto Encyclopedia o f Genes and
Genomes website (http ://www. genome.j p/kegg/pathway/map/mapOO 190. html).
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oligonucleotides were used in matched RT-PCR reactions, along side of GAPDH
primers and probe, see Methods. Despite a success in measuring GAPDH transcript
levels in these RNA samples, initial reactions using COX Vla-H primers did not work
properly (data not shown). Upon closer examination of the COX Vla-H genomic
sequence (Genbank accession number, U34801), it became apparent that the COX VlaH primers spanned an intron and, thus, they did not permit detectable amplification of
genomic DNA in Taqman® PCR reactions. Since these reactions were used as standards
to quantify mRNA levels of our unknown samples, an alternative approach was devised.
Genomic DNA was replaced in the standard curve reactions with reaction dilutions from
several pooled RT reactions. Using this strategy, it was determined that COX Vla-H
transcripts increase greater than 20-fold after 24 hours in chloramphenicol-treated cells
and this increase was significantly higher (P<0.00001) than in EtOH-treated controls
(Figure 16). Thus, the RT-PCR results confirm the microarray finding that
chloramphenicol affects transcripts of this particular gene.
To extend these results, several additional experiments were performed. We
added chloramphenicol to BB88 cultures to examine effects of chloramphenicol
treatment times on relative COX Vla-H transcript levels. Figure 17 plots the fold
increases from 3 separate time-courses. These results show that there is little change in
COX Vla-H transcript levels until about 12 hours (one cell doubling). Thereafter, COX
Vla-H transcript levels increase in chloramphenicol-treated cells relative to COX Vla-H
transcript amounts in matched untreated control cells, reaching half-maximum increase in
about 19 hours. Between 24 hours and our last time point at 50 hours, increases in COX
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C o n tr o l

T r e a te d

Figure 16. Treatment of BB88 Cells with Chloramphenicol Causes Increases in COX
Vla-H Transcripts.
RT-PCR was performed on two Control (0.1% EtOH) and two Treated (50pM
chloramphenicol) RNAs (RNAs were the same as in Figure 1) to determine the COX
Vla-H transcript amounts in these RNAs, see Methods. Each RT-PCR reaction was
done in triplicate. Plots show the fold increase of COX Vla-H transcripts in Treated
(chloramphenicol) versus Control (EtOH) RNA samples normalized to GAPDH, see
Methods. Control value represents the mean of six pairwise determinations, while the
Treated value represents the mean from twelve determinations. COX Vla-H from treated
cells is increased >20-fold over COX Vla-H RNA in control cells (*, P<0.00001 equal
variance t-test).

Vla-H transcripts appear to have slowed, with increases measuring approximately 20and 30-fold, respectively (Figure 17). In a concentration-response experiment, we
measured changes in COX Vla-H transcript levels in BB88 cells treated with various
amount of chloramphenicol. Figure 18 shows that after 24 hours treatment,
chloramphencicol causes a concentration-dependent increase in COX Vla-H transcripts.
The data was analyzed using a four-parameter model of non-linear regression. The data
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Figure 17. Effects o f Chloramphenicol on COX Vla-H RNA in BB88 Cells Over Time.
Proliferating BB88 cells were treated with 50 pM chloramphenicol and RNA was
isolated from cells after various treatment times. Fold increases in COX Vla-H RNA
levels were determined using RT-PCR reactions from three separate experiments, see
Figure 12 and Methods. Squares represent the mean values of a minimum of duplicate
determinations from RT-PCR reactions done in triplicate. Data were analyzed in
GraphPad Prism and the curve fitted using non-linear regression-sigmoidal dose
response. (ECso= 19 hours and R2= 0.65).

fit the model quite well [R2 = 0.95] with a half maximal increase in COX Vla-H
transcript (EC 50) occurring at 33 pM chloramphenicol.
Next, we measured the effect of other antibiotics on BB88 cell proliferation and
COX Vla-H transcript levels. Figure 19A compares the effect of chloramphenicol,
erythromycin, Geneticin, and tetracycline on BB88 cell growth to their respective
diluents. At the concentrations selected, all the antibiotics inhibited BB88 cell
proliferation after 24 hours. RNA was isolated from each of these single cultures and
while yields of total RNA from the cultures were comparable (data not shown), levels of
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Figure 18. Fold Increases in COX Vla-H Transcripts in BB88 Cells Treated for
24 Hours with Various Amounts of Chloramphenicol.
BB88 cells were seeded at ~20K/ml. After 16 hours, cultures were counted and treated
with various amounts of chloramphenicol (0-200 pM). 24 hours later, RNA was
prepared for Taqman RT-PCR studies, see Figure 3 and Methods. Squares represent the
mean fold increase in COX Vla-H transcripts in RNA from three treated versus three
untreated (0.1% EtOH) control BB88 cultures. Data were analyzed in Graph Pad Prism
using a 4-parameter model of non-linear regression-sigmoidal dose response, EC 50- 33
pM and R2=0.95.

COX VTa-H transcript in each culture varied (Figure 19B). The amounts of COX Vla-H
transcripts were significantly (P<0.007) higher in all antibiotic-treated BB88 cells relative
to the transcript levels in diluent-treated control cells. To determine whether this effect
was specific for COX Vla-H transcripts, effects on two related nuclear transcripts were
measured (Figure 20). Using nucleotide sequences with accession numbers M37831 and
X53157, primers and probes were designed for measuring transcripts to COX IV and
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Figure 19. Effect o f Antibiotics on BB88 Cell Proliferation and COX Vla-H Transcript
Levels.
Cells were seeded as in Figure 18. After 24 hours, various antibiotics were added.
A. After an additional 24 hours in culture, cells were counted and harvested. Bars
represent the cell counts from individual cultures. B. RNA was isolated from harvested
BB88 cells and then the COX Vla-H transcript levels were determined in each sample,
see Figure 13 and Methods. Bars represent the mean fold increase of treated versus
control from six RT-PCR determinations. Using a two-sample, unequal variance t-T est;
*, P<0.007 for antibiotic versus water control, **, P< 0.0001 for antibiotic versus
ethanol control, and ***, P<0.002 for antibiotic versus DMSO control.

COX Vb subunits, respectively, see Methods and Table 4. Figure 20A and 20B show the
fold increases in COX IV and COX Vb in transcripts the various RNA samples. While
our RT-PCR assay easily detected COX IV and COX Vb transcripts, most of the RNAs
for these COX subunits remained unchanged. The only change was a decrease in COX
IV transcripts in RNA from chloramphenicol-treated BB88 cells (P<0.035).
In an attempt to understand better the mechanism by which compounds may be
affecting BB88 proliferation, we decided to experiment with several additional
compounds (Figure 21). First, we examined the effects of compounds PNU-86983 and
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Treatment

Treatment

Figure 20. Effect o f Antibiotics on Transcript Levels of COX IV and COX Vb Subunits.
Fold increases in. COX IV transcript (A) and COX Vb transcript (B) were determined
from the same RNAs as prepared in Figure 19. Bars represent the mean of six RT-PCR
determinations. There is no difference between any of the antibiotic treatments on these
RNAs, except for the RNA levels for COX IV in chloramphenicol-treated BB88 cells
versus the ethanol (EtOH) control (*, P<0.035).
PNU-78714. These two compounds have been shown to inhibit smooth muscle growth
through an undefined mechanism (Bonin, Singh, Gammill, & Erickson, 1993; Erickson et
al., 1994). We wanted to see whether the chloramphenicol effects in BB88 cells were
somewhat selective or if these two compounds inhibited BB88 growth and increasd
COX Vla-H mRNA levels also. In the 24 hour-treated cultures done here, both 25 piM
PNU-86983 and PNU-78714 inhibited BB88 cell growth by 45% and 25%, respectively
(Figure 21 A). These effects on proliferation were accompanied by increases in COX
Vla-H transcripts of about 5- fold (PNU-86983) and 8-fold (PNU-78714) over the
transcript levels in DMSO-treated controls (Figure 2 IB). In the same experiment, we
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Figure 21. Effect o f Compounds on BB88 Cell Growth and COX Vla-H Transcript
Levels.
BB88 cells were seeded as in Figure 18 and various compounds were added after 24
hours. After an additional 24 hours, cells were counted and harvested (A). RNA was
prepared from cells and fold increases of COX Vla-H transcript levels were determined
as described in Figure 12 and Methods. Bars represent the mean of at least triplicate
RT-PCR determinations from total RNA prepared from single cultures (B). (*, P<0.04,
**, P,0.0008, ***, P<0.002).

treated BB88 cells with oligomycin, a potent uncoupler of oxidative phosphorylation
(Nagamune et al., 1994). In twenty-four hours, 250 pM oligomycin inhibited BB88 cell
proliferation and enhanced COX Vla-H transcript levels, 13% and 4-fold, respectively
(Figure 21A and B). In our last experiment, we observed the effects of succinylacetone
on BB88 growth and COX Vla-H transcript levels (Figure 22). Succinylacetone is an
inhibitor of delta aminolevulinate dehydratase (ALAD) (Woodard & Dailey, 2000). This
enzyme plays a role in the synthesis of heme, an important component of hemoglobin.
We wanted to know if this disruption in heme biosynthesis affected proliferating BB88

Reproduced with permission o f the copyright owner. Further reproduction prohibited without permission.

86
cells similar to chloramphenicol. While 50 pM chloramphenicol inhibited BB88 cell
proliferation and increased COX Vla-H transcript levels, 1 mM succinylacetone had no
effect on growth or COX VTa-H transcripts (Figure 22A and B).

Treatment

Treatment

Figure 22. Effect of Succinylacetone on BB88 Cell Growth and COX Vla-H Transcript
Levels.
A. Effect of Succinylacetone on BB88 proliferation. Cells were seeded as in Figure 14
and succinylacetone was added after 24 hours. Cells were counted and harvested after
an additional 24 hours. Bars represent the cell counts from individual cultures. B. Effect
of compounds on COX Vla-H transcript levels in proliferating BB88 cells. Bars
represent the mean fold increase in COX Vla-H RNA determined by triplicate RT-PCR
determinations using RNA isolated from cultures described in A.
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DISCUSSION
As a consequence of chloramphenicol-induced myelosuppression, there may be
gene expression changes that accompany and perhaps cause inhibition of erythroid cell
proliferation. In order to see if we could identify antibiotic-induced changes in gene
expression in erythroid cells, we decided to study the effects of chloramphenicol on
cultured BB88 murine erythroleukemia cells. These murine erythroleukemia cells are
easy to culture and under our culture conditions, have a doubling time of 12 hours
(Figure 6). After 48 hours of treatment, chloramphenicol inhibits BB88 cell growth with
an EC 50 of 43 pM (Figure 7), a concentration within this antibiotic’s therapeutic serum
concentration of 10-15 pg/ml (-30-50 pM) (Soldin, Golas, Rajchgot, Prober, &
MacLeod, 1983; Wilson & Cockerill, 1987). Previous studies have examined changes
occurring to cultured mammalian cells after longer chloramphenicol treatment (Holt,
Andrews, Payne, Williams, & Turton, 1997; Kong, Holt, Ma, Lie, & Chan, 1999; Leiter
et al., 1999; Kang 2005). In these studies, long-term (days) chloramphenicol treatment
was causing apoptosis in erythroid cells. In this work, we focused on the early anti
proliferative effects of chloramphenicol where we observed proliferation changes within
24 hours of treatment (Figure 8). It should be added that chloramphenicol inhibits
reversibly erythroleukemia cell proliferation (Kang et al., 2005). We treated BB88 cells
with chloramphenicol for 24 hours and then removed the antibiotic by washing the cells.
Treated , then washed BB88 cells returned to proliferating similar to untreated cells
(data not shown). This reversible effect is what has been seen clinically for this antibiotic
87
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and other antimicrobials (Kuter & Tillotson, 2001). Nagiec et al. (2005) determined that
the oxazolidinones reversibly inhibit K562 human erythroleukemia cell proliferation in
vitro. In addition, they showed that cells without mitochondria and treated with
oxazolidinones proliferate, suggesting a link between proliferation and mitochondrial
function. These results suggest that the BB88 cells are sensitive in a way that make them
an appropriate model for examining the relationship between chloramphenicol’s effects
on proliferation and gene expression.
Microarray technology is a powerful tool in that global transcription changes can
be studied in one experiment. This technology is being used to identify the effects of a
wide variety of xenobiotics and has opened a whole new field of study named
toxicogenomics, see Introduction (Rouse & Hardiman, 2003, Borlak, 2005). We
attempted to use this technology to identify transcripts in BB88 cells that are sensitive to
chloramphenicol. We first needed to validate Affymetrix microarray methods and
procedures. There are two parts to this technology. There are experimental procedures
involved in preparing cRNA Targets from experimental and control cells, hybridizing
these Targets to Probe Sets on commercial murine microarrays, and then detecting each
Target/Probe Set signal by scanning the microarray. Next, there are the analytical and
bioinformatic procedures that are used to establish the significance of each data point,
record, or hybridization signal. Both parts of the experimental exercise are labor
intensive and developing. This technology and area of research is not without
controversy. There have been recent reports with mixed results concerning the
reproducibility and standardization of microarray experiments (Bammler, 2005; Waring
et al., 2005). Nevertheless, the attractiveness of being able to examine large numbers of
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transcriptional changes in a single experiment prompted us to use and validate this
technology. We followed the Asymetrix protocols as closely as possible, see Methods
and Affymetrix Microarray Suite User’s Guide version 5.0, and although there are ways
to ensure success of RNA preparation and cRNA Target synthesis, this technology is
evolving. We have used a variety of analytical techniques, such as quantitation and
DNAse treatment of total RNA (Figures 5,9, 10 and data not shown), Agilent
Bioanalyzer gel analysis of fragmented cRNA Target samples (Figure 11), and
hybridization to Test2 Arrays (data not shown) to increase our confidence to the results
we received. In the case of Test2 arrays, these are more affordable micorarrays
containing probe sets of spiked controls (eg BIOB) and housekeeping genes from a
variety o f organisms. While we did not use Test2 arrays in this particular experiment, we
have used them to assess the quality of our cRNA Targets in other Affymetrix
micorarray experiments. Since the U74Av2 microarrays contained the same spiked
controls (see Methods) and many of the same murine control transcripts that are on the
Test2 array, we decided to assess the cRNA Target and hybridization quality by
performing one hybridization to these microarrays.
At any time in any cell, the number of genes being transcribed is limited. Also,
those expressed genes are represented by differing amounts of RNA. A significant
concern is whether this technology, or any current RNA quantitation technology for that
matter, can be used to determine low copy transcripts. Even though the cRNA Target is
an amplified representation of all the mRNAs in our total RNA, are we able to detect
low-level transcripts or subtle changes in transcript levels using this technology? Put
another way, are we to believe the changes we see in transcripts with very low Signals.
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Affymetrix Analysis software has attempted to address this issue by attaching statistical
significance (P-value) not only to each individual Signal, but also calculating a P-value
for each computed fold change between any two microarray comparisons, see Methods
and Table 5. We have included in our analysis a sum of singles (sos) calculation as an
added tool to assess transcriptional changes, see Appendix B. Using the sos calculation,
we may argue that one of the genes, 101845_s_at, whose transcripts increase
significantly in our experiment (Affymetrix Change p-value equals 0.0024), but whose
sos is 197, is not worthy of inclusion in the list of increased transcripts. Another issue
with the microarray technology is dealing with the random fluctuations in cellular
transcription (Figure 12). When comparing RNAs from the zero hour control cells to
RNAs from cells grown in 0.1% EtOH for 24 hours, there were 3,809 increased or
decreased transcripts out of a total of 74928 comparisons. This 5% represented a net
change of only eight transcripts, all which increased slightly. From information obtained
from NetAffx Analysis Center, four of the eight transcripts were annotated, data not
shown. Probe Set Name 98603_s_at codes for RAN GTPase activating protein 1, a
protein involved in mitosis and spindle assembly (Trieselman 2002). Another transcript,
Probe Set Name 95133_at, codes for aspargine synthetase. This protein is involved in the
control of growth or amino acid metabolism and is regulated by amino acid availability
(Fafournoux, Bruhat, & Jousse, 2000). In this culture, perhaps amino acid pools declined
prompting this increase. Probe Set Name 96596_at codes for TDD5, a phosphorylated
stress-responsive protein whose phosphorylation may be related to cell growth
(Agarwala, Kokame, Kato, and Miyata, 2000). Finally, Probe Set Name 160464_s_at
codes for the cytoplasmic protein Ndrl and is probably the same gene as Probe Set
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Name 96596_at (Agarwala et al., 2000). These limited changes, now totaling 7
transcripts being changed in all 6 comparisons, suggest that 0.1% EtOH treatment causes
few transcriptional changes in BB88 cells and correlate with the effects seen on
proliferation. Unexpectedly, when we compared transcript changes within the 24 hour
0.1% EtOH control groups, the results are rather different. Here, for the three
comparisons, out of a total of 37,464 comparisons (12,488 transcripts per U74Av2
microarray), 2,641 (880 average changed transcripts per comparison) (7%) transcripts
are increased or decreased. In further examination of the 2641 changed transcripts, there
were 95 transcripts common to all three 24 hours control comparisons. Since these
RNAs were from the same treatment group, we would have expected fewer
transcriptional changes amongst these RNAs. However, upon a closer examination of the
within group comparisons, the number of transcript changes between U74Av2 control
micorarray #3 vs #2, U74Av2 micorarray #9 vs #2, and U74Av2 micorarray #9 vs #3
were 633, 834, and 1174, respectively, data not shown. The number of changes in this
first comparison, U74Av2 control micorarray #3 vs #2, matches closely the average
number (634) of transcriptional changes we saw in the inter-control group comparisons,
see Figure 12. Thus, there may be issues with the U74Av2 control micorarray # 9 and/or
this particular sample RNA that surfaced only upon these analyses. It must be
emphasized that the whole transcript profiling process involves a number of steps, such
that any issue with a particular step may translate into downstream transcript changes.
For example, RNA preparation, ds-cDNA synthesis, and cRNA Target amplification are
manipulations where differences may occur. Obviously, while costly, the more replicate
microarray hybridizations will eliminate some issues with random fluctuations in
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transcript levels and enhance the sensitivity of any experiment. Also, using RT-PCR,
could have been used to confirm these changes seen between control cultures.
As we expected to see with the intra-group control comparisons discussed above,
there were much fewer changes when comparing chloramphenicol-treated RNAs with
one another, see Figure 13. There was an average of 163 changes per comparison
(%1.3). This represents only three transcripts that were commonly changed in the three
comparisons, and none were changed more than two-fold. Despite the Affymetrix
software assigning significance to these changes, we feel that these changes are random
fluctuations accounting for the inherent noise in the datasets. When comparing
chloramphenicol-treated RNAs with control (0.1% EtOH) RNAs, a total of 112,392
comparisons were done and there were 11,789 changes (1309 average changes per
comparison, see Figure 13 and 14A). This number of changes suggests that on any
treated microarray, 10% of the transcripts levels were different than on a control
microarray. However, since random fluctuations occur, both within the treated and
control groups respectively (see above), then the real changes may be substantially less,
perhaps approaching 1.7% [10%-(7% +1.3%)]. Using Spotfire, we were able to capture
199 transcripts that were commonly changed in all nine comparisons. This number of
changed transcripts is 1.5% of the total number transcripts (12488) per individual
comparisons per chip (Figure 14C). These results were re-assuring as they were close to
our theoretical calculations and they suggest that these changes are the result of
chloramphenicol treatment.
Regardless of any problems concerning the identification of genes with subtle
expression changes, our experiments have provided us with some noteworthy changes.
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O f these 199 transcripts, 56, representing a total of 52 genes, were increased or
decreased greater than or equal to two-fold (Figure 14D and Table 5). Table 5
summarizes what we found out about these transcripts and some gene ontology patterns
have emerged. First, some of the largest changes occurred in transcripts that encode
proteins involved in transcription. Even though the changes in transcript levels were not
so dramatic like with COX Vla-H, even small changes in transcription factor levels can
cause dramatic and amplified changes downstream. To see if there may be direct effects
o f chloramphenicol on transcription factor expression, a timecourse would help. Next,
from the list of decreased and increased transcript lists, there were three and four genes
that are involved in glucose metabolism, respectively. Of the genes sensitive to
chloramphenicol, this number represented 13.5% of the total. By blocking mitochondrial
protein synthesis, chloramphenicol appears to affect expression of nuclear genes involved
in bioenergetics and metabolism. Down-regulation of such genes as Gpd2, a nuclearencoded mitochondrial protein that is responsible for converting glycerol-3-phosphate to
dihyroxyacetone phosphate, manifests this disruption. This process shuttles electrons at
the level of Coenzyme Q, yielding to ATP production. While some mammalian cells use
this energy shuttle, most cells prefer a more energy efficient system that uses malate and
aspartate. In the case of transcript increases, the affected genes appear to be involved in
mitochondrial electron transport (Tabe 5B). Here, chloramphenicol treatment may be
stimulating gene expression to compensate for the reduction in mitochondrial proteins
and the decline in ATP production. In terms of compensation, it was interesting to see
that chloramphenicol caused increases in transcripts that code for proteins involved in
amino acid transport and biosynthesis. Recently, Priquone and Cortopassi have been
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studying mitochondrial deletions and showed that in osteosarcoma cells ATG12, a
transcript involved in the autophagy pathway, is induced by chloramphenicol treatment
(Priqione & Cortopassi, 2007). Further they showed that autophagy is accompanied by a
decline in the concentration of intracellular amino acids in these cells. They argue this
decline results from decreases in proteasomal activity. Here, while we did not measure
amino acids levels in BB88 cells nor did we observe autophagy, perhaps all the increases
we saw in transcripts involved in amino acid metabolism are compensating for effects of
autophagy. Another compensatory mechanism may be the increased inositol phosphate
receptor expression (Table 5B). Criollo et al. (2007) have been studying autophagy also
and they have shown that declines in intracellular levels of 1,4,5-inositol phosphate and
its receptor induce autohapgy. Again, we did not measure inositol phosphate levels in
chloramphenicol-treated BB88 cells, however we did see an increase in the transcripts
for Itpr2, an inositol 1,4,5-triphosphate receptor. In relation to other’s works on
autophagy, our profiling results are intriguing.
Individually, there have some noteworthy changes in certain genes’ transcript
levels. From this group, three transcripts stood out. The first transcript, 101793_at,
increased 37-fold (log2=5.2) and codes for the Fc portion, high affinity I, of IgG
receptor. While the relationship between this cell surface immunoglobulin and
chloramphenicol is not known, there is a report suggesting that this protein is related to
stress and could act as an immunotoxin (Tur et al., 2003). Even though the relationship
between proliferation and immunotoxon activity is unclear, perhaps the stress caused by
chloramphenicol treatment is manifested by an increase in transcript levels for
101793_at. In the case of Probe Set Name 93738_at, transcript levels declined about 5-
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fold (log2=-2.38). This transcript codes for the facilitated glucose transporter. One can
speculate that the effects of chloramphenicol on mitochondrial protein synthesis and
hence respiration are causing a direct decline in the use of glucose. This decline may
cause a decrease in the facilitated glucose transporter. Kansara and Berridge (2004) have
shown that glucose transport tracks with the cell cycle. Expression of the facilitated
glucose transporter in BB88 cells may be declining as a response to changes in the cell
cycle. Kang et al. (2005) showed that long-term chloramphenicol treatment of K562
cells causes a decline in both translation and transcription of E2F-1 and cyclin D l, two
cell cycle regulatory molecules. In the same cells, Leiter et al. (1999) reported that
growth inhibition caused by 8 days of chloramphenicol treatment was associated with
slight increases and decreases in the numbers of cells in G1 and S phase, respectively.
While we saw no transcription changes in cell cycle genes, nor did we examine BB88 cell
cycle profiles, we have shown that chloramphenicol inhibits BB88 cell growth by
increasing its doubling time (Figure 8). Further, Nagiec et al. (2005) reported that short
term treatment of K562 human erythroleukemia cells with the oxazolidinones, antibiotics
that inhibit MPS synthesis similar to chloramphenicol, also cause proliferation inhibition.
Their findings suggest that the oxazolidinones do not cause cell cycle arrest, but affect
growth by elongating the cell cycle. Therefore, perhaps the decline in the glucose
transporter expression is tied to affects chloramphenicol has on the cell cycle. The third
transcript, 99667_at, increased about 28-fold (log2=4.8) in chloramphenicol-treated
cells. Since 99667_at transcripts code for subunit Via of cytochrome c oxidase (COX)
(see Table 5 and Figure 15), the terminal enzyme complex in the mitochondrial electron
transport chain (Capaldi, 1990) and because there is a direct link between
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chloramphenicol and mitochondrial function (Leiter et al., 1999), we chose to study this
transcript change further. Interestingly, subunit Via is not necessary for COX assembly,
but it appears to modulate the enzyme’s activity through interactions with ATP
(Taanman & Capaldi, 1993). Also, in a COX assembly study, subunit Via associated
with S3 (COX subcomplex) suggesting that this subunit has a regulatory role (Nijtmans,
Taanman, Muijsers, Speijer, & Van Den Bogert, 1998). Most likely, as a result of
chloramphenicol’s effect on the synthesis of COX, COX VTa-H expression increases. In
mammals, subunit Via exists as two isoforms, -H (heart) and -L (liver). Originally, these
designations implied tissue-specific expression, although it appears now that these
designations are interpreted as heart/muscle and constitutive forms, respectively (Ewart,
Zhang, & Capaldi, 1991, Wan & Moreadith, 1995). From our experiments, it appears
that subunit Vla-H is uniquely expressed in BB88 cells and its transcript is increased
upon chloramphenicol treatment (Table 5 and Appendix B). Not only were we surprised
by the magnitude of this increase, but that the COX Vla-H transcript was present at all.
This finding may be the first report where this transcript has been found in
erythroleukemic cells. Further, we observed that transcripts for the Vla-L isoform or
other nuclear encoded COX subunits were not identified on the microarrays as having
increased or decreased, data not shown.
We chose to use Taqman® PCR to confirm and expand on the microarray
findings for COX Vla-H. RT-PCR confirms the finding that COX Vla-H transcripts are
increased in proliferating BB88 cells. Initially, we were confounded by our
measurements of COX Vla-H transcript in our RNA samples. There were fluorescent
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signals coming from the experimental RNA samples, but the genomic standard control
reactions were blank. Upon closer examination, it was discovered that the COX Vla-H
primers were designed to a region of the mRNA spanning an intron. Thus, when using
genomic DNA as a template, a PCR product was being synthesized that was too long
and therefore was sub-optimal for Taqman® PCR. Therefore, the RT-PCR strategy was
re-evaluated, and, rather than designing new oligonucleotide primers and probe, RT
reactions made from RNA from several antibiotic-treated BB88 cells were pooled and
used as a quantitative control, see Methods. Since the concern was to measure changes
in COX Vla-H transcript levels between various RNAs from treated BB88 cells, these
reactions were sufficient to use as standards for determining relative COX Vla-H
transcript levels throughout this study. Another issue was the selection of a
“housekeeping” control gene. Typically, a housekeeping gene is a constitutive gene that
is transcribed independent of experimental conditions. While many genes have been
designated housekeeping genes, the truth is no single housekeeping gene always
manifests constant expression levels under all conditions (Bustin 2000; Doroudi 2002).
While we selected glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as our
housekeeping control gene to normalize the transcript levels for COX Vla-H, we
measured some variation in GAPDH mRNA levels in our samples, data not shown.
Nevertheless, Taqman® PCR confirmed that COX Vla-H transcripts increased greater
than 20-fold in proliferating BB88 cells treated with 50 pM chloramphenicol for 24
hours (Figure 16). This increase was slightly less than the increase we determined using
Affymetrix MAS 5.0 software in the microarray experiment (Table 5). Taqman® PCR
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has been determined to be very accurate; so even though the differences between the two
methods o f COX Vla-H measurement are less than two-fold, the results suggest that
further experimental’comparisons will be necessary to validate microarray methods
(Bustin 2000). Also, it should noted that there was variation in COX Vla-H transcripts
levels within our Taqman® PCR experiments reported here; compare Figures 16, 18, 19,
21, and 22. We speculate that some of these differences may have resulted from real
biological differences within the BB88 cultures or some of the variation may have
resulted from the housekeeping gene normalization issue discussed above. Regardless,
chloramphenicol causes time- and concentration-dependent changes in the relative
amounts of COX Vla-H mRNA and these changes are probably due to transcriptional
changes (Figure 17 and Figure 18).
Results from Taqman RT-PCR time-course experiments suggest that
chloramphenicol affects COX Vla-H after about one cell doubling (Figures 6 and Figure
17). If chloramphenicol affected COX Vla-H transcription directly, we might have
expected to see its transcript level change earlier. Rather, increases in COX Vla-H
transcripts coincided with chloramphenicol’s anti-proliferative effects, where effects
were seen in growth and COX Vla-H transcript levels after 24 hours and 12 hours,
respectively (Figure 8 and Figure 17). This result extended what we saw during our
transcript profiling work. Results from our concentration-response experiment
suggested that chloramphenicol has an EC50 = 33 pM with respect to increases in COX
Vla-H transcript after 24 hours. This concentration matched nicely with
chloramphenicol’s effect on cell proliferation. The proliferation inhibition EC50 measured
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in BB88 cells was 43 pM (Figure 7). These results suggest a link between changes in
COX Vla-H transcripts and proliferation. Another piece of evidence that we had hoped
would support this link was a finding that COX Vla-H transcript levels decline in
differentiating BB88 cells treated with chloramphenicol. Marks and Rifkind (1989)
showed that treatment of BB88 cells with polar compounds such as hexamethylene
bisacetamide (HMB A) causes cell differentiation. Further this process is accompanied by
a decline in cell proliferation. Kaneko et al. have shown that early addition of
chloramphenicol to differentiating mouse erythroleukemia cells here inhibited this type of
erythroid induction (Kaneko, 1988). In our hands however, preliminary experiments
using chloramphenicol with HMBA-treated BB88 cells, there was no detectable affect on
COX Vla-H mRNA (data not shown). This result may reflect the developmental pattern
of regulation for this particular COX subunit, whereby COX Vla-H may not be
expressed in differentiating BB88 cells (Ewart, 1991).
When BB88 cells were treated with other antibiotics, increases in COX Vla-H
transcripts accompanied cell proliferation inhibition (Figure 19). Despite all the
antibiotics inhibiting BB88 proliferation, the affect on COX Vla-H was somewhat
surprising. Initially, we had expected there to be more selectivity of these antibiotics.
However, since all these antibiotics are known bacterial protein synthesis inhibitors,
perhaps this result is not so surprising. Others have shown a correlation between cell
proliferation and mitochondrial function (Leiter et al., 1999; Kim et al., 2001; Nagiec et
al., 2005). Perhaps as a result of these antibiotics affecting BB88 mitochondria similarly,
there is a reduction in respiration and cellular ATP levels fall. Lower ATP levels in BB88
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cells may have an effect on subunit COX Vla-H protein and the other nuclear encoded
mitochondrial proteins whose transcripts levels were shown to increase upon
chloramphenicol treatment (Table 5). Interestingly, the effect of chloramphenicol and
other MPS inhibitors appeared to be specific for this particular COX subunit, as
transcript levels of two additional nuclear-encoded COX subunits were unaffected by the
antibiotics or respiratory inhibitors tested (Figure 20). These results extended the
findings using Affymetrix microarrays. Gene ontology analysis revealed that despite
chloramphenicol treatment affecting transcripts for only a few nuclear-encoded
mitochondrial proteins, these affected proteins are involved in electron transport,
gluconeogenesis, ion transport, and ATP-dependent protein hydrolysis (Table 5). These
gene products appear sensitive to the effects these antibiotics have on mitochondrial
bioenergetics and respiration.
PNU-86983 and PNU-78714 may be inhibiting BB88 cell proliferation and
increasing COX Vla-H transcript levels similar to chloramphenicol (Figure 21).
However, there may be some subtle differences here. In a personal communication with
EwaNagiec, a scientist at Pfizer, Inc., we learned that when she treated rho zero cells
with the aminochromone PNU-86983 and chloramphenicol, there were differences. Rho
zero cells are human osteosarcoma 143B cells depleted of their mitochondria. This
depletion occurs as a result of prolonged exposure to ethidium bromide, a chemical that
binds to DNA and inhibits mitochondrial DNA replication. In Nagiec’s experiments,
PNU-86983 inhibited rho zero cell proliferation in a concentration-dependent fashion,
whereas, while chloramphenicol inhibited parental 143B cell growth, it had no effect on
rho zero proliferation (Nagiec et al., 2005). These results suggest that the
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aminochromones do not affect proliferation via inhibiting MPS and more importantly
point toward MPS as being a very important factor in control over cellular proliferation.
These differences may be reflected in the extent to which COX Vla-H transcript levels
are increased (Figure 21). In a personal communication with Paul Bonin, another Pfizer
scientist, he explained that the aminochromones have been tested in a variety of assays,
and, thus far, these compounds appear only to inhibit mammalian cell proliferation
(Bonin, 1993; Erickson, 1994). Oligomycin is an antibiotic that is a potent uncoupler o f
oxidative phosphorylation by inhibiting ATP synthase (Nagamune, 1993). This antibiotic
inhibited BB88 cell proliferation (Figure 21). These experiments were somewhat difficult
to perform. Not only was oligomycin quite potent, but also its effect on BB88 growth
occurred within a narrow concentration range. Nevertheless, in line with the relationship
between mitochondrial function, cell proliferation, and COX Vla-H transcription, COX
Vla-H mRNA increased 4-fold in cells treated 24 hours with 250 pM oligomycin (Figure
21). This compound may also have affects on MPS as oligomycin is a macrolide, a class
of antibiotic that inhibits bacterial protein synthesis
Finally, we tested succinylacetone, a compound that affects heme production by
inhibiting the enzyme delta-Aminolevulinate dehydratase (ALAD) in erythroid and nonerythroid cells (Woodard & Dailey, 2000). The results we obtained with succinylacetone
were a little surprising since researchers have shown that 2 mM succinylacetone inhibited
growth and decreased respiration in proliferating leukemia cells in vitro (Weinbach &
Ebert, 1985). We found that 1 mM succinylacetone not only did not inhibit BB88 cell
proliferation, but also had no effect on COX Vla-H transcript levels. It is possible that
the differences here could be that Weinbach and Ebert used 2-4 mM succinylacetone.
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Perhaps the 1 mM concentration that we used was insufficient to inhibit ALAD
completely (Ebert, Hess, & Tschudy, 1985; Weinbach & Ebert, 1985). Further, in a
study examining tissue variant effects of heme biosynthesis inhibitors, this compound has
been shown to inhibit transcript levels for mitochondrial-encoded COX I and COX II
subunits and a nuclear-encoded COX Vb subunits (Vijayasarathy, Damle, Lenka, &
Avadhani, 1999). We speculated that, since chloramphenicol inhibits cell growth, affects
MPS, and inhibits hemoglobin production in differentiating erythroleukemia cells
(Kaneko, 1988), we might have found some common effects of chloramphenicol and
succinylacetone. It turns out; 1 mM succinylacetone had no effect on BB88 cell
proliferation, nor was there an effect of this ALAD inhibitor on COX Vla-H mRNAs
(Figure 22). These results were somewhat unexpected, since chloramphenicol also
decreased transcript levels for ALAD in proliferating BB88 cells and succinylacetone
inhibited growth of HeLa cells after 5 days in culture (Ye & Zhang, 2004). Thus, it
appears that chloramphenicol and succinylacetone affect BB88 cells differently.
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CONCLUSION
Chloramphenicol affects mammalian cells and clinically this effect has manifested
itself in myelosuppression. In an attempt to understand the myelosuppression that has
accompanied chloramphenicol usage, we have examined the effects of chloramphenicol
on murine erythroleukemia BB88 cells. These cells have proven to be an excellent model
for studying the anti-proliferative effects of chloramphenicol. Chloramphenicol inhibits
BB88 proliferation in a time- and concentration-dependent fashion. To begin to
understand the cellular changes that accompany chloramphenicol’s more immediate
effects on proliferation, we implemented and validated the Affymetrix Microarray
technology platform. This platform allowed us to observe changes occurring to
approximately 6000 annotated gene transcripts and about 6,000 ESTs per U74Av2
Array in one experiment. By studying the early transcriptional changes resulting from
chloramphenicol treatment, we have shown there is a correlation with the effects we see
ft.

on proliferation. Under the experimental protocol we followed, we implemented and
designed some relatively simple analytical methods to identify genes that may be
increased or decreased in chloramphenicol-treated proliferating BB88 cells. In analyzing
transcripts that decreased or increased two-fold or more, some patterns emerged.
Notably, chloramphenicol affected nuclear-encoded transcripts involved in transcription
control, mitochondrial electron transport and bioenergetics, and amino acid transport and
metabolism.
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Most interesting was the finding that in BB88 cells treated for 24 hours 50 pM
chloramphenicol, there is a dramatic increase in mRNA for COX Vla-H, a subunit of
COX. While the function for COX Vla-H and most of the other nine nuclear-encoded
mammalian COX subunits remains unclear, COX Vla-H may play an important role
regulating mitchondrial energy metabolism (Kadenbach, Huttemann, Arnold, Lee, &
Bender, 2000). Given that efficient cell proliferation depends on a functional electron
transport system and mitochondrial energy production, we decided to study further this
particular COX subunit. Using Taqman® PCR, we confirmed that proliferating BB88
cells contain COX Vla-H mRNA. To our knowledge, this finding is novel. Previous
reports have not identified expression of COX Vla-H in erythroid cells (Grossman &
Lomax, 1997). Unfortunately, an antibody to the murine COX Vla-H isoform does not
exist; so we were unable to confirm whether protein levels matched mRNA levels.
However; in murine BB88 erythroleukemia cells treated with chloramphenicol, we have
shown that mRNA for the COX Vla-H subunit increases in a time- and concentrationdependent fashion The effects on COX Vla-H transcripts appear to be specific; as other
nuclear-encoded COX transcripts are unaffected by antibiotic treatment. At this time, it
appears that COX Vla-H transcripts may be a biomarker for BB88 proliferation, as the
changes we see in COX Vla-H transcript levels mimic chloramphenicol’s effects on
proliferation. Other compounds that are known to affect MPS or respiration inhibit
BB88 proliferation and cause increases in COX Vla-H transcripts. These results match
what we see with chloramphenicol treatment and suggest that chloramphenicol may be
inhibiting cell proliferation and increasing COX Vla-H transcripts by affecting
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mitochondria. Since we used undifferentiated cells, our experimental results may not
translate perfectly to what happens clinically. However, compared with other tissues in
the body, erythroid stem cells are proliferating continually, and differentiating cells are
utilizing their mitochondria for energy and heme biosynthesis. Hence, despite the fact
that other cells respond to chloramphenicol, this population of cells may be highly
sensitive to the compounds that target mitochondria. In the short term, chloramphenicol
inhibits cell proliferation through its effects on mitochondria and in our model of
erythroid cell proliferation these inhibitory effects are manifested by changes in COX
Vla-H expression. While further experiments are needed to definitively link COX VTa-H
with proliferation, the evidence supports a role for this subunit in cell growth.
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> Date: Tue, 15 M a y 2007 19:38:03 -0400
> Subject: Re: Figures
> From: Christop her Walsh < c h r i s t o p h e r _ w a l s h @ h m s .h a r v a r d . e d u >
> To: <p k w h @ c h a r t e r m i .n e t >
>
> Peter, you can ce rtainly have p ermiss ion
to use the figures but I
do not have the specific chapter opener art work any more. Chris W a l s h
>

>
> On 5/14/07
wrote:

11:52 PM,

"pkwh0charterrni.net" < p k w h 0 c h a r t e r m i .net>

>

> > Dr. Walsh:
> >

> > As part of m y scientific studies on c hloramphenicol toxicity, I
have read your excellent 2003 book, Antibiotics: Actions, Origins,
Resistance.
> >

> > I was w o n d e ring whether there would be a w ay for me to use a few
of your Figures in m y thesis introduction. Specifically, I am
int ere s t e d in using the chapter 3-6 opener Figures de pictin g
ant ibioti c mode of actions.
> >

> > Of course I w o u l d give credit b y referencing this mater i a l and/or
the appropr iate individual, John Trauger, res ponsible for the artwork.
> >

> > If permis s i o n is given, I would like to know also w h eth er there
are electronic files of these Figures available that w o u l d ma ke their
use easier.
> >

> > Thanks.
> >

> > Peter Harris
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#
Decreased
1
2
3
4
5
6
7

Probe Set
Name
94995 at
104701 at
98984 f at
103362 at
160091 at
93330 at
93738 at

average
treated
signal
429
403
497
342
2654
554
101

#
Increased
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31

Probe Set
Name
101793 at
99667 at
101845 s at
101209 at
161067 at
102249 at
102879 s at
101429 at
103006 at
102292 at
103922 f at
94359 at
97398 at
96199 at
104144 at
102313 at
102770 at
92925 at
160108 at
103921 i at
98122 at
101441 i at
94278 at
92589 at
96160 at
100306 at
100592 at
100920 at
160602 at
103520 at
97960 at

average
treated
signal
1500
3095
180
432
3835
2967
1843
3200
1019
2323
4890
461
3758
501
2247
1321
2711
3021
595
1334
496
1369
2196
5137
2506
403
11164
291
1656
232
460

average
control
signal
885
858
883
978
8496
1734
449
average
control
signal
67
50
17
55
707
470
206
652
199
568
974
75
799
171
765
345
883
1156
202
670
186
445
728
1833
794
148
4123
174
706
121
186

average
signal
log2
ratio
-1.0
-1.0
-1.1
-1.2
-1.3
-1.5
-2.4
average
signal
log2
ratio
5.2
4.8
4.1
3.0
2.7
2.6
2.4
2.4
2.1
2.1
2.0
1.9
1.9
1.7
1.7
1.6
1.6
1.5
1.5
1.5
1.5
1.4
1.4
1.3
1.3
1.3
1.3
1.3
1.2
1.2
1.2

ave.
signal
ratio
-2.06
-2.13
-1.78
-2.86
-3.20
-3.13
-4.45

Change
p-value
1.00E+00
1.00E+00
1.00E+00
1.00E+00
1.00E+00
1.00E+00
1.00E+00

average
sos
1314
1261
1380
1320
11150
2288
550

ave.
signal
ratio
22.4
61.8
10.5
7.8
5.4
6.3
8.9
4.9
5.1
4.1
5
6.1
4.7
2.9
2.9
3.8
3.1
2.6
2.9
2
2.7
3.1
3
2.8
3.2
2.7
2.7
1.7
2.3
1.9
2.5

Change
p-value
3.10E-05
0.00E+00
2.38E-03
3.11E-04
1.00E-06
1.00E-06
0.00E+00
0.00E+00
2.10E-05
1.00E-06
1.00E-06
4.00E-06
0.00E+00
1.00E-06
2.00E-06
1.00E-06
3.00E-06
0.00E+00
1.77E-04
3.10E-05
7.40E-05
1.30E-05
3.00E-06
0.00E+00
4.67E-04
6.30E-05
0.00E+00
1.00E+00
1.20E-05
1.54E-04
0.00E+00

average
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1567
3145
197
487
4542
3437
2049
3852
1218
2891
5864
536
4557
672
3012
1666
3594
4177
797
2004
682
1814
2924
6970
3300
551
15287
465
2362
353
646
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#
Increased
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

Probe Set
Name
161221 f at
95637 at
100599 at
92268 at
94135 at
98042_at
160530 at
160535 at
100943 at
102337 s at
103818 at
160328 at
104328 at
97268 i at
160463 at
99330 at
97870 s at
95502 at

average
treated
signal
1145
1045
19818
2626
729
302
1475
2923
1735
835
1721
6502
1318
13077
962
716
3992
1278

average
control
signal
520
426
8734
1152
342
140
720
1438
848
434
819
3070
750
5859
504
353
2139
826

average
signal
log2
ratio
1.2
1.2
1.2
1.2
1.2
1.1
1.1
1.1
1.1
1.1
1.1
1.0
1.0
1.0
1.0
1.0
1.0
1.0

ave.
signal
ratio
2.2
2.5
2.3
2.3
2.1
2.2
2
2
2
1.9
2.1
2.1
1.8
2.2
1.9
2
1.9
1.5

Change
p-value
1.33E-04
1.00E-06
1.00E-06
1.00E-06
4.70E-05
1.43E-04
3.70E-05
0.00E+00
2.90E-04
2.30E-05
5.90E-05
3.00E-06
3.40E-05
1.00E-06
1.30E-03
1.88E-03
5.00E-06
1.00E-06
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average
sos
1665
1471
28552
3778
1071
442
2195
4361
2583
1269
2540
9572
2068
18936
1466
1069
6131
2104
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